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CHAPTER I 
 
INTRODUCTION 
1. Gene therapy  
 
Gene therapy is a methodology for correcting defective genes responsible for 
disease development. Two methods are available for inserting genetic material 
into human chromosomes. The first, called the ex vivo technique, involves 
surgically removing cells from the patients, injecting or splicing the new DNA 
(the DNA that will correct the disease) into the cells and letting them divide in 
cultures. The new tissues are placed back into the affected area of the patient. 
The second method is called in vivo technique that consist in the direct injection 
of therapeutic DNA into the body cells. A carrier molecule called vector must be 
used to deliver the therapeutic gene to the patient's target cells. Currently, the 
most common vectors are viruses that have been genetically altered to carry 
normal human DNA. Viruses have evolved a way of encapsulating and delivering 
their genes to human cells in a pathogenic manner. Scientists have  take advantage 
of this capability and manipulated the virus genome to remove disease-causing 
genes and insert therapeutic genes.  Target cells such as the patient's liver or lung 
cells are infected with viral vectors. The vectors then unload their genetic material 
containing the therapeutic human gene into the target cells. The generation of a 
functional protein product from the therapeutic gene restores the target cell to a 
normal state. Some of the different types of viruses used as gene therapy vectors:  
• Retroviruses  
• Adenoviruses  
• Adeno-associated viruses  
Besides virus-mediated gene-delivery systems, there are several nonviral options 
for gene delivery. The simplest method is the direct introduction of therapeutic 
DNA into target cells. This approach is limited in its application because it can be 
used only with certain tissues and requires large amounts of DNA.  
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Another nonviral approach involves the creation of an artificial lipid sphere with 
an aqueous core. The liposomes, which carry therapeutic DNA, are capable of 
passing the DNA through the target cell's membrane.  Therapeutic DNA also can 
be introduced in target cells by chemically linking the DNA to a molecule that 
will bind to special cell receptors. Once bound to these receptors, the therapeutic 
DNA constructs are engulfed by the cell membrane and passed into the interior of 
the target cell. This delivery system tends to be less effective than other options. 
Gene therapy includes some of problems that the scientists are trying to solve:  
1) Short-lived duration of gene therapeutic approch: before gene therapy can 
become a permanent cure for any condition, the therapeutic DNA introduced into 
target cells must remain functional and the cells containing the therapeutic DNA 
must be long-lived and stable. Problems with integrating therapeutic DNA into the 
genome and the rapidly dividing nature of many cells prevent gene therapy from 
achieving long-term benefits. At the moment patients should undergo multiple 
rounds of gene therapy. 
2) Immune response: anytime a foreign object is introduced into human tissues, 
the immune system is designed to attack the invader. The risk of stimulating the 
immune system in a way that reduces gene therapy effectiveness is always a 
possibility.  
3) Multigene disorders: conditions or disorders that arise from mutations in a 
single gene are the best candidates for gene therapy. Unfortunately, some of the 
most commonly occurring disorders, such a heart disease, high blood pressure, 
Alzheimer’s disease, arthritis, and diabetes, are caused by the combined effects of 
variations in many genes. Multigene or multifactorial disorders such as these 
would be especially difficult to treat effectively using gene therapy. 
4) Chance of inducing a tumor (insertional mutagenesis): if the DNA is integrated 
in the wrong place in the genome, for example in a tumor suppressor gene, it 
could induce a tumor. This has occurred in clinical trials for X-linked severe 
combined immunodeficiency (X-SCID) patients, in which hematopoietic stem 
cells were transduced with a corrective transgene using a retrovirus, and this led to 
the development of T cell leukemia in 3 of 20 patients.  
 
 - 3 - 
2. Biology and viral life cycle of adenovirus 
2.1 Description and general properties of adenoviruses 
 
Adenoviruses were first discovered half a century ago by Rowe and colleagues, 
who were trying to culture adenoid tissue in the laboratory (Rowe et al., 1953). 
Non human adenoviruses have been isolated from a number of species including 
chimpanzees, pig, mouse, dog, and other mammalian and avian species (Shenk, 
1996). Although human adenoviruses cause significant levels of respiratory, 
ocular and gastrointestinal disease, they have been the object of intense study over 
the years mainly as a model system for basic eukaryotic cellular processes such as 
transcription, RNA processing, DNA replication, translation and oncogenesis. 
Currently, adenoviruses are a popular choice as a gene delivery vehicle and in all 
gene therapy clinical trials are second only to the use of retroviral vectors. 
Adenoviruses belong to family of Adenoviridae; currently, the 51 serotypes of 
human adenovirus are divided are in six groups (A to F) based on sequence 
homology and their ability to agglutinate red blood cells (Shenk, 1996). The 
adenovirus genome is a double-stranded, 36-kb approximately long linear DNA. 
Each end of the genome has an inverted terminal repeat (ITR) of 100-140 bp to 
which the terminal protein (TP) is covalently linked. Adenoviruses have a 
characteristic morphology (Stewart et al, 1993).  The capsid, a proteic structure 
that covers the adenovirus genome is icosahedral. The capsid vertices consist of 
the penton base, which acts to anchor the fibre protein, responsible for primary 
attachment of virions to the cell surface. The facets of the virus capsid are 
composed primarily of trimers of the hexon protein, as well as a number of other 
minor components including protein pIIIa, pVI, pVIII and pIX (Fig. 1). The 
protein VII, a small peptide termed mu (Anderson et al., 1989) is intimately 
associated with the virus DNA, while the protein V, is packaged with this DNA-
protein complex and appears to provide a structural link to the capsid via protein 
VI (Matthews and Russel, 1995). Members of adenovirus family infect a great 
variety of post-mitotic cells, even those associated with highly differentiated 
tissues such as skeletal muscle, lung, brain, and heart. Since they deliver their 
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genome to the nucleus and can replicate with high efficiency, they are prime 
candidates for the expression and delivery of therapeutic gene and have a wide 
host-range. 
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Figure 1 Adenovirus structure: A) A stylized section of the adenovirus particle 
based on current understanding of its polypeptide components and DNA. No real 
section of the icosahedral virion would contain all the components. Virion 
constituents are designated by their polypeptide numbers with the exception of the 
terminal protein (TP). B)  Adenovirus seen through electron microscopy. 
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2.2 The viral life cycle 
2.2.1 Binding and entry 
 
For all groups, except group B adenoviruses, initial attachment of virion particles 
to the cell surface occurs through binding of the fibre Knob to the receptor that is 
identical to that for Coxsackie B virus (Bergelson et al., 1997) and has therefore 
been termed the coxsackie/adenovirus receptor (CAR). This is a plasma 
membrane protein of 46 kDa belonging to the immunoglobulin superfamily and 
contains extracellular, transmembrane and cytoplasmic domains (Tomko et al., 
1997), with extracellular domain being sufficient for attachment. (Wang and 
Bergelson, 1999). CAR normally functions as a cell-to-cell adhesion molecule on 
the basolateral surface of epithelial cells (Honda et al., 2000). The CD46 
molecule, a complement- regulatory protein, has been identified as a cellular 
receptor for group B adenoviruses (Gaggar et al., 2003). 
After initial attachment (Fig.2) to the cell surface, an exposed RGD motif on the 
penton base interacts with member of αν integrin family, triggering virus 
internalization by clathrin- dependent, receptor-mediated endocytosis (Stewart et 
al., 1997; Meier et al., 2000) Integrins form a large family of heterodimeric 
receptors and it appears that integrins ανβ3 e ανβ5 both support adenovirus 
internalization ανβ5 is expressed on human bronchial  epithelial cell, a major site 
of primary adenovirus infection in vivo (Mette et al., 1993). Interaction of the 
virus with plasma membrane can induce a number of signalling pathways such as 
the activation of the phosphoinositide-3-OH kinase (PI-3k) pathway, which in 
turn triggers the Rho family of GTPases and the polymerization and 
reorganization of actin to facilitate endocytosis (Li et al., 1998; Rauma et al., 
1999).  
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Figure 2 Binding and internalization of Adenovirus:  A) the adsorption of the 
virus to target cell receptors involves high-affinity binding via the knob portion of 
the fibre. The prime receptor for human Adenovirus serotype 5 is identical to that 
for coxsackie B virus and has been named the Coxsackie/Adenovirus receptor 
(CAR). After the attachment step, B) interaction between the penton base and αν 
integrins on the cell surface leads to internalisation of the virus through 
endocytosis. 
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As early as 20 min post-infection, activation of Raf/mitogen- activated protein 
Kinase   (MAPK) pathway and consequential production of IL-8 have been 
observed (Bruder and Kovesdi, 1997). 
For Ad2 and Ad5, the acidic environment of the endosome induces escape of 
virions into the cytoplasm, although the mechanisms underlying this process are 
poorly understood. Once in the cytoplasm (Fig.3), dynein mediates trafficking of 
virions along microtubules toward the nucleus, where they subsequently dock 
with the nuclear pore complex (NPC) (Trotman et al., 2001; Kelkar et al., 2004). 
Disassembly of the capsid at NPC allows for import of the viral genome and 
commencement of the viral transcriptional program.  
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Figure 3 Model for nuclear entry of Ad2: The Ad2 particle docks on the 
cytoplasmic fibrils of the nuclear pore by binding CAN/Nup214. Small amounts 
of histone H1 escape from the nucleus and bind to hexon protein on the proximal 
side of the docked capsid. Importin −importin 7 dimers bind to H1, inducing 
import of the proximal H1−hexon complexes and triggering capsid disassembly. 
Consequently, the viral DNA is liberated near the opening of the pore and 
positioned for translocation into the nucleus.  
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2.2.2 Early genes and DNA replication 
 
The adenovirus infectious cycle can be defined into two phases: the “early” phase 
and the “late” phase, respectively occurring before and after virus DNA 
replication (Fig. 4). The first phase covers the entry of the virus into the host cell 
and the passage of the virus genome to the nucleus, followed by the selective 
transcription and translation of the early genes. These early events modulate the 
functions of the cell so as to facilitate the replication of the virus DNA and the 
resultant transcription and translation of the late genes. This leads to assembly in 
the nucleus of the structural proteins and the maturation of infectious virus. The 
early phase in a permissive cell can take about 6-8 h (depending on a number of 
extraneous factors), while the late phase is normally much more rapid, yielding 
virus in another 4-6 h. 
The first viral transcription unit to be expressed is E1A that produces multiple 
mRNA and protein products by way of differential mRNA processing. Two E1A 
transcripts are produced during early infection: 13S mRNA encoding the 289R 
(where R stands for amino acid residues) protein in (Ad5) and 12S mRNA 
encoding the 243R. These proteins can immortalize primary cells in culture and, 
when expressed in conjunction with E1B proteins, cause tumours in rodents 
(reviewed by Ben- Israel and Kleinberger, 2002). During infection, the E1A 
proteins function to trans-activate the other adenovirus early transcription units 
(E1B, E2, E3 and E4) and to induce the cell to enter S phase in order to create an 
environment optimal for virus replication (Berk, 1986).  
The E1A proteins have been shown to use a variety of mechanisms to subvert cell 
cycle checkpoints ; E1A can directly bind and inhibit components involved in cell 
cycle control such as the cyclin-dependent kinase inhibitor p21 (Chatopadhyay et 
al., 2001 ). Furthermore, E1A can interact with a number of host factors involved 
in mediating chromatin structure including p400 (Fuchs et al., 2001) and the 
histone acetyltransferases (HATs) p300/CBP, p CAF and TRRAP/GCN5 (Lang 
and Hearing, 2003). 
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Figure 4 Transcription of the adenovirus genome: The early transcripts are 
outlined in green, the late in blue. Arrows indicate the direction of transcription. 
The gene locations of the VA RNAs are denoted in brown. MLP, Major late 
promoter. 
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Cell cycle deregulation by E1A results in accumulation of the tumour suppressor 
p53 and expression of E1A during infection promotes apoptosis by sensitizing 
cells to the tumour necrosis factor α (TNF- α) and TRAIL (TNF- related 
apoptosis-inducing ligand)-mediated death receptor pathways (Routes et al., 
2000). The E1B 19K product is able to block downstream mediators of these 
pathways and inhibit programmed cell death (Perez and White, 2000) In the case 
of TNF- α mediated apoptosis, the E1B-19k protein can bind directly to the 
proapoptotic proteins Bak and Bax to prevent mitochondria-mediated apoptosis 
(Sundararajan et al., 2001 ). In addiction to its antiapoptotic functions, the E1B-
55K protein facilitates the transport of viral mRNAs to the cytoplasm during the 
late stages of infection (Pilder et al., 1986). 
The E2 region encodes proteins necessary for replication of the viral genome: 
DNA polymerase, preterminal protein, and 72-kDa single-stranded DNA-binding 
protein. These provide the machinery for replication of virus DNA action and 
ensuing transcription of late genes and this is mediated by interaction with a 
number of cellular factors. Products of the viral E3 region, which are dispensable 
for the replication of virus in tissue culture, function to subvert the host immune 
response. The immune system has evolved a number of mechanisms for 
destroying virus-infected cells, including cell lysis by cytotoxic T lymphocytes 
and activation of receptor- mediated apoptotic pathways by chemokines. The E3-
gp19k protein act in two ways to prevent the presentation of viral antigens by the 
MHC class I pathway and subsequent cell lysis by cytotoxic T cells.  E3-gp19k 
was first found to prevent translocation of MHC class I molecules to the cell 
surface by sequestering them in the endoplasmatic reticulum. More recently, it has 
been shown that E3-gp19k can bind  to TAP (transporter associated with antigen 
processing ), an ER protein responsible for transporting cytosolic antigens into the 
lumen, suggesting that the E3-gp19k protein may directly interfere with the 
loading of peptides onto MHC class I molecules (Bennet et al 1999). The E3-
10.4K, 14.5K and 14.7K proteins have all be shown to inhibit the induction of 
apoptosis by the chemokines TNF-α Fas ligand (FasL), and TRAIL. 
The E4 transcription unit encodes a number of proteins (termed orfs 1-6/7) that 
have been known to play a role in cell cycle control and transformation. E4orf1 
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protein of Ad9 demonstrated that it is able to induce estrogens-dependent 
mammary tumours in mice (Javier et al., 1991). In Ad2 and Ad5, E4orf3 and 
E4orf6 encode gene products with a number of diverse functions. Both proteins 
have been shown to increase the ability of E1 genes to transform primary rodent 
cells, increase the expression of viral late genes and inhibit genome 
concatemerization by cellular DNA repair enzymes (Stracker et al., 2002). In the 
case of E4orf6, enhanced transformation is thought to occur via its ability to block 
p53-mediated trans-activation by inhibiting the binding of p53 cellular 
transcription factors (Dobner et al., 1996). In addition to the function listed, 
E4orf3 protein also mediates the organization of nuclear structures termed PML 
oncogenic domains. Although the function of these domains is not clear they have 
been shown to play a role in transformation, transcription, and apoptosis in 
infected cells (reviewed by Maul, 1998).  Most products of the E4 region have 
antiapoptotic effects; however, the E4orf4 interacts with protein phosphatase 2A 
to stimulate p53 independent apoptosis (Shtrichman et al., 1999) 
2.2.3 Late gene expression and viral assembly  
 
The major late promoter (MLP) transcribes adenovirus late genes that are 
expressed from five regions, L1-L5. The major late transcription unit (MLTU) 
encodes approximately 15 to 20 different mRNAs, all of which are derived from a 
single pre-m RNA by differential splicing and polyadenylation. These transcripts 
primarily encode structural proteins of the virus and other proteins involved in 
virion assembly. After the onset of DNA replication, transcription from the MLP 
is induced to high levels, ensuring the production of adequate amounts of 
structural proteins for the assembly of progeny virions. Manipulation of late genes 
encoding the structural components of the capsid has been explored as a strategy 
for changing the tropism of gene therapy vectors. The L1-52/55k protein is 
required for the encapsidation process, while  L4-33K protein also appears to play 
a role in virus assembly as mutants  carrying complete or partial  deletions of this 
gene are defective in capsid formation ( Finnen et al., 2001 ). 
The packaging sequence itself is a series of seven repeats (A1-A7) and the left end 
of the genome (Hearing et al., 1987). Although each of the repeats fits a 
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consensus motif, they are nay functionally equivalent as A1, A2, A5 and A6 have 
been shown to be most important for genome encapsidation (Grable and Hearing, 
1990). Once assembly and DNA encapsidation have occurred, the adenovirus 
protease cleaves a subset of the structural proteins into their mature form to 
produce fully infectious virions (reviewed by Mangel et al., 2003). Cell lysis and 
release of progeny virions occur approximately 30hr post infection in a process 
involving the E3-11.6K protein, also called the adenovirus death protein (ADP); 
(Tollefson et al 1996a). Unlike other products of the E3 region, ADP is produced 
only during the late phase of infection and is transcribed from the MLP rather than 
E3 promoter (Tollefson et al 1996b). 
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3. Adenoviruses as vectors 
 
Adenoviruses can infect a wide variety of cell types and tissues in both dividing 
and non-dividing cells. This characteristic, together with their relative ease of 
preparation and purification, has led to their extensive use as a gene vectors.  
Vectors (Table 1) can be utilized for: 1) cancer therapy to deliver genes that will 
lead to tumour suppression and elimination; 2) gene therapy 3) supplementary 
therapy to deliver genes, expression of which will combat disease process. 
 
 
Table 1 General properties of adenoviral vectors 
3.1 First-generation vectors 
 
In the first generation of vector, the E1 region necessary for activation of viral 
promoters and expression of both early and late genes, were removed and so this 
viruses are severely impaired in their ability to replicate. For these reasons, 
replacement of the E1 region with transgenes was the initial strategy used in 
construction of adenoviral vectors, giving rise to the so-called first-generation 
vectors. The ability to delete E1 region is made possible by the existence of cell 
lines that provide these functions in trans. The classic cell line for this purpose is 
the 293 cell line, a human embryonic kidney-derived line that has been 
transformed by the adenovirus E1 region (Graham et al., 1977) Production of E1 
deleted vectors was initially carried out by homologous recombination in 
 - 16 - 
mammalian cells between constructs carrying the left and right ends of the 
genome (Chinnadurai et al., 1979). Removal of the E1 region alone allows 
approximately 5.1 kb for insertion of therapeutic genes because adenovirus can 
package up 38 kb without affecting viral titer and growth rate (Bett et al., 1993).  
Many of the first-generation vectors also contain a deletion in the E3 region, 
mainly for practical reasons. To optimize the yield of vectors in early experiments 
using overlap recombination, investigators used the Ad type 5 mutant dl309 or its 
derivates, which contain in the E1 region two unique restriction sites due to partial 
deletion of E3 (Jones and Shenk 1978).  
Thus, the likelihood of regeneration of the starting wild-type virus, which could 
arise as a result either of incomplete restriction digestion or religation of viral 
DNA in the cell, was minimized. Furthermore, E3 genes are entirely dispensable 
for virus growth in vitro and their removal, together with deletion of E1 genes, 
allows up to 8.2 kb for transgenes insertion. Data have suggested that expression 
of E3 genes from vectors may be beneficial in vivo because of their ability to 
dampen many host immune processes. It has been reported that expression of the 
entire E3 region or the E3-gp19K product alone can increase persistence of 
transgene expression in some rodent models (Ilan et al., 1997). However, 
conflicting data have shown that expression of the E3-gp19K protein has no effect 
on the length of transgene expression (Schowalter et al., 1997). These 
discrepancies may be due in part to differences in the nature of the transgene or 
the tissue type that was analyzed. Nevertheless, the inclusion of E3 genes in 
vectors remains an area of active investigation. 
Although first-generation vectors have proven to be highly promising as vehicles 
for gene delivery, problems do exist. The first drawback associated with these 
vectors becomes apparent during vector production. Recombination between the 
E1 region sequences in the complementing cell line and the recombinant virus can 
give rise to viral progeny with functional E1 genes that are replication competent 
(Lochmuller et al., 1994). 
Thus, recombinant virus stocks must be assayed for the presence of replication-
competent viruses. Helper cell lines such as PERC6 and 911, in which the overlap 
between E1 sequences in the cell and those commonly present on recombinant 
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virus chromosomes is reduced, have been constructed in order to minimize this 
occurrence . The second and more troublesome problem associated with the use of 
first generation vectors is their stimulation of a cellular immune response, 
resulting in the destruction of transduced cells that are expressing therapeutic 
transgenes. Indeed, a number of early studies showed that administration of E1-
deleted vectors to immune-competent animals results in only transient transgene 
expression (Dai et al., 1995). It is theorized that the immune response is 
stimulated by low levels of replication that can occur even in the absence of the 
E1 genes. This idea is supported by findings that genome replication and late gene 
expression can occur from E1-deleted vectors in vivo (Yang et al., 1994a, b). 
Although stimulation of a robust immune response may preclude the use of first-
generation vectors in some settings, they remain promising for applications 
requiring short-term gene expression such as cancer therapy and vaccination. 
 
3.2 Second-generation vectors 
 
To prevent the immune response generated by low-level replication of E1-deleted 
viruses, vectors deleted for multiple genes have been created to inhibit viral gene 
expression more effectively. These second-generation vectors have been 
constructed primarily by the removal of E2 and E4 coding sequences, also 
providing the benefit of a larger capacity for transgene insertion. The major 
drawback encountered during construction of these multiply deleted viruses is the 
need for isolation of cell lines expressing the missing functions in trans. Although 
this can be a time-consuming process, vectors propagated in these cells are less 
likely to undergo recombination to give replication-competent viruses. In the case 
of E2 genes, cell lines have been produced that stably express the single stranded 
DNA-binding protein, preterminal protein, the viral DNA polymerase, or a 
combination of the three (Amalfitano and Chamberlain, 1997). Vectors containing 
deletions in these genes are incapable of genome replication, and in the case of 
polymerase-deficient vectors, no replication occurs even in the presence of high 
levels of E1A (Amalfitano et al., 1998). 
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3.3 Helper-dependent vectors 
 
The approach that holds perhaps the most promise for long-term gene expression 
in the absence of complicating effects due to the presence of viral genes is that of 
gutted, or helper-dependent, adenovirus vectors (Clemens et al., 1996; Chen et al., 
1997). In this strategy, all of the viral structural genes are deleted from the viral 
chromosome, leaving just the two ITRs and the packaging signal. Such a 
chromosome can accommodate up to 37 kb of transgene sequences. To propagate 
the helper-dependent genome, the presence of a helper virus that provides the 
functions required for replication and assembly is required, as production of a 
complementing cell line has not been possible because of the need for high levels 
of some virion components and the toxicity of some of these proteins to the cell. 
The main problem to date is the inability to completely separate virions containing 
the helper-dependent chromosome from those containing the helper virus genome 
(Sandig et al., 2000). Early strategies that were pursued to reduce helper virus 
contamination included the use of a helper virus carrying a mutated packaging 
signal, and minimizing the size of the helper-dependent chromosome compared 
with that of the helper virus with the hope that the two types of virions could be 
separated based on their different densities. Even using these techniques, 
however, helper-dependent virus preparations contained significant levels of 
contaminating helper virus. More recently, helper viruses in which the packaging 
sequence is flanked by loxP or frt sites have been constructed (Umana et al., 
2001). When these viruses are used to propagate helper-dependent vectors in cells 
expressing Cre and Flp, respectively, the packaging sequence on the helper virus 
is excised, resulting in a significantly lower percentage of contaminating helper 
virus. Indeed, by deriving improved helper cell lines and culture conditions, 
helper virus levels can be reduced to below 0.01% (Palmer and Ng, 2003). 
However, recombination between helper-dependent and helper chromosomes, 
leading to helper chromosomes that can be packaged, is still encountered during 
virus propagation. A novel method using baculovirus to provide helper functions 
was reported to allow for production of helper-dependent vectors without 
contamination by helper virions, although attempts to use this process
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scale preparations also resulted in the formation of replication-competent viruses 
(Cheshenko et al.,2001). Nevertheless, in vivo studies using helper-dependent 
vectors have produced promising results (Pastore et al., 2004). 
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3.4 Induction of innate immune response and toxicity by adenoviral 
vectors 
 
The primary function of the host immune response to a virus is to detect rapidly, 
limit and ultimately eradicate an infection. The innate immune system plays a key 
role as the first line of defense in this process. 
The cellular immune response towards adenovirus antigens is activated by 
antigen-presenting cells (APCs). After the uptake of the Ad particle, viral proteins 
and transgenes products are processed into small oligopeptides, which are 
presented by the major histocompatibility complex (MHC) class-I molecules at 
the cell surface. It is noteworthy that the de novo synthesis of viral proteins does 
not appear to be required for antigen presentation, since psoralen-treated, UV-
cross-linked, inactive adenovirus vectors still cause activation of a cellular 
immune response ( Kafri T, Morgan D, Krahl T, et al. 1998 ) The binding of 
CD8+ T cells to this peptide–major histocompatibility complex (MHC) class-I 
initiates the formation of Ad-specific or transgene-product-specific CTLs  (Fig.5). 
The interaction between CD28 and B7 plays a co-stimulatory role in this 
activation (Linsley PS, Brady W, Grosmaire L, et al, 1991). The cellular immune 
response is further stimulated by CD4+ helper cells primarily belonging to the 
Th1 subset (Yang Y, Xiang Z, Ertl HC, Wilson JM, 1995). In contrast to the 
CD8+ T cells, these CD4+ helper cells are activated by epitopes from the input 
virion, which are presented by MHC class-II molecules at the surface of APCs. 
This activation triggers the Th1 cells to secrete interleukin-2 (IL-2) and interferon-
gamma (IFN-γ). These cytokines, in turn, induce the differentiation of CD8+ T 
cells into CTLs (Maraskovsky E, Chen WF, Shortman K. 1989) In addition, IFN- 
γ causes the up  regulation of MHC-I expression in Ad-transduced cells and 
consequently facilitates their recognition by CTLs. Moreover, activated CD4+ 
helper cells have also been suggested to destroy Ad-transduced cells themselves, 
resembling in this way primary CTLs (Yang Y, Wilson JM, 1995). 
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Figure 5 Development of adenoviral (Ad) vector immunity: The first use of an 
Ad vector leads to a strong innate as well as adaptive immune responses resulting 
in development of neutralizing antibodies and elimination of transduced cells. In 
response to high amount of vector administration, a strong innate immune is 
initiated, which is characterized by production of a variety of proinflammatory 
cytokines and chemokines leading to an acute toxic response and hepatotoxicity. 
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Apart from the cellular immune response, the adaptive immune system also 
includes a humoral component, which constitutes a second hurdle to persistent 
transgene expression. This humoral immune response is initiated by the binding of 
adenovirus particles to the surface immunoglobulin of B cells (Janeway CA, 
Travers P, 1997). After internalization and processing of the virus, the adenovirus 
derived epitopes are presented at the surface of the B cell by MHC-II molecules.  
The resulting antigen–MHC-II complex can be recognized by activated T helper 
cells of the Th2 subset (Paul WE, Seder RA, 1994). 
This specific CD4+ helper cell subset releases cytokines, like IL-4, IL-5, IL-6 and 
IL-10, which provide indispensable signals for the B cells to differentiate into 
plasma cells. As a result, the plasma cells secrete antibodies (Abs), which are 
directed towards the adenoviral capsid. Although T helper cells of the Th1 subset 
are poor initiators of the humoral immune response, they do play a role in Ab-
isotype switching ((Boom WH, Liano D, Abbas AK, 1988).  Whereas Th2 cells 
control the production of the Abs isotypes IgG1, IgG2b, IgA and IgE by 
cytokines, such as IL-4, Th1 cells control the switch to IgG2a or IgG3 by means 
of IFN-γ secretion (Finkelman FD, Holmes J, Katona IM, et al. 1980). The 
development of Ad-specific antibodies does not contribute to the elimination of 
Ad-transduced cells and hence does not affect the persistence of transgene 
expression. However, Ad-specific Abs will bind the Ad vector and thereby 
prevent cell entry and promote opsonization by macrophages. Consequently, Ad-
specific Abs hampers the efficacy of repeated administrations of the Ad vector, 
which would be required to keep the transgene expression at the desired level. 
Thus, although repeated administrations of the Ad vector can prolong expression 
of the transgene in immunodeficient recipients, the efficiency is dramatically 
reduced in immunocompetent recipients (Dai Y, Schwarz EM, Gu D, et al. 1995). 
Moreover, a large proportion of the human population harbours humoral 
immunity to Ad vectors because of previous infections (Chirmule N, Propert K, 
Magosin S, et al, 1999). Consequently, effective adenovirus-mediated gene 
transfer in humans may be frustrated even at the first administration of an Ad 
vector (Fig.6). It is noteworthy that vector-specific immunity does not prevent the  
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Figure 6 Pre-existing immunity as a barrier to adenoviral (Ad) gene therapy: 
The presence of pre-existing immunity in the majority of human population 
interferes with initial transduction with HDAd vectors. In case of individuals with 
no pre-existing immunity, the first inoculation with an HDAd vector may be 
successful but subsequent development of strong cellular and humoral immunity 
renders repeat administration of the same vector less effective.  
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vector-specific activation of the innate immune system that occurs at very-high 
vector doses (Varnavski AN, Zhang Y, Schnell M, et al. 2002). 
Apart from Ad-specific Abs, neutralizing Abs might also be generated against the 
transgene product.  
This transgene-product-specific Abs can neutralize the transgene product once it 
enters the circulation and thereby abrogate the effect of gene transfer, 
irrespectively of persistence of transgene expression (Fields PA, Kowalczyk DW, 
Arruda VR, et al.2000). Moreover, several studies have indicated that, instead of 
the immunogenicity of adenoviral proteins, the immunogenicity of foreign 
transgene-encoded proteins is a primary determinant of the persistence of 
transgene expression (Morral N, O’Neal W, Zhou H, Langston C, Beaudet A, 
1997). 
The contribution of foreign transgene products to the observed immune responses 
is not unexpected, but it represents a substantial hurdle for gene therapy of 
hereditary diseases. The immune response to the transgene product may be 
dependent on the nature of the mutation that affects the endogenous gene. 
Recently, it has been demonstrated that persistent expression of the foreign 
antigen (i.e. clotting factor IX in an murine haemophilia B model) may even 
induce tolerance to the therapeutic antigen (Mingozzi F, Liu YL, Dobrzynski E, et 
al.2003). 
 The immunogenicity of the transgene may be depend on the synthesis of the 
neoantigen in the antigen-presenting cells.( De Geest BR, Van Linthout SA, 
Collen D,2003)  Hence, it will be essential to monitor immune responses to the 
transgene products in all patients enrolled in gene-therapy studies. 
Obviously, strategies to prevent the cellular and humoral immune responses, e.g. 
adaptive immunity towards the adenovirus vector and to the transgene product 
may lead to significant improvement of gene therapy of hereditary diseases. 
Hence, research is mainly focused on these components of the host’s immune 
response. However, the innate immune responses, as a first line of defence also 
influence vector persistence. The non-specific innate immune response acts 
rapidly after viral entry. The early phase of the host’s immune response is 
predominantly brought about by neutrophils, macrophages and natural killer (NK) 
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cells and lasts about 4 days, until the adaptive immune response is fully activated. 
(Ginsberg HS, Prince GA. 1994). 
 The activation of the adaptive immune response is much more rapid upon re-
infection of the same pathogen, which is due to the so-called immunologic 
memory. 
After intravenous administration of a first-generation Ad vector to 
immunocompetent and immunodeficient mice, 90% of the viral genome was 
eliminated from the liver within the first 24 h. Similar vector elimination was seen 
after intratracheal administration, although in this case the vector loss was 70% 
within 24 h Worgall S, Leopold PL,Wolff G, et al 1997). After the fatal incident 
in a clinical trial for treatment of patients with a deficiency in the liver enzyme 
ornithine transcarbamylase (OTC) ( Raper SE, Yudkoff M, Chirmule N, et al. 
2002) , it became evident that the innate immune system is highly activated by 
intravascular administration of high doses of Ad vectors (Zhang Y, Chirmule N, 
Gao GP, et al.2001) . In mice, macrophages and dendritic cells mediate an acute 
cytokine response. Within 6 h high amounts of IL-6, IL-12 and TNF-α are 
released. So, besides modulation of the adaptive immune response, the 
modulation of the early immune responses might also be required to facilitate 
effective gene transfer in vivo with Ad vectors. 
In summary, the host response to adenovirus occurs in three phases in animal 
models and humans (Trapnell, B.C., et al 2002, Pastore, L., et al 1999). 
The first phase occurs as early as 1 hour after systemic administration of the virus 
and continues for 4 days and is characterized by thrombocytopenia, intense 
periportal polymorphonuclear leukocyte infiltration, and elevated liver enzymes 
(Raper, S.E., et al 2002; Morral, N et al 2002; Lozier, J.N. et al 2002; Nunes, F.A. 
et al 2002). These effects are largely due to activation of Kupffer cells which 
produce and release several cytokines (IL-1, IL-6, TNF-α) and chemokines (MIP-
2, MCP-1, IP-10 and RANTES) into the general circulation for the recruitment of 
inflammatory cells (Muruve, D.A et al 1999; Lieber, A. et al 1997). In addition, 
macrophages and dendritic cells in the spleen and peritoneum also release 
significant amounts of chemokines and cytokines into the circulation, contributing 
to neutrophil-dependent hepatic injury and progression toward the second phase 
 - 26 - 
of the inflammatory process (Zhang, Y., et al 2001; Jooss, K. et al 2003). It is 
thought that virus capsid proteins alone are responsible for induction of the acute 
phase of the immune response (Brunetti-Pierri, N et al 2004; Higginbotham, J.N. 
et al 2002; Schnell, M.A., et. Al 2001). 
The second phase of the immune response begins 5-7 days after administration of 
vector and is directed against newly transduced cells. During this intermediate 
phase, Ad-specific CD8+ T cells directed against cells expressing viral genes and 
transgene products are generated (Jooss, K., et al 1998 Morral, N., et al 1997; 
Yang, Y., et al 1996 Yang, Y. et al 1994). Helper CD4+ T cells, largely stimulated 
by the presence of adenovirus capsid proteins, are also generated (Kafri, T et al 
1998 Yang, Y., 1995). Removal of transduced cells by activated lymphocytes 
significantly limits the duration of transgene expression in the immunocompetent 
host and is responsible for inducing a self-limited inflammation in the liver 
(Christ, M., et al 2000. Worgall, S., et al 1997). At high viral loads, this can 
progress to severe and lethal liver necrosis, disseminated intravascular 
coagulopathy, bleeding and, in a few cases, a severe immune response syndrome 
characterized by multiorgan failure and sepsis (Raper, S.E., et al 2003 Lozier, 
J.N., et al  1999). These effects have been seen in the clinic and in nonhuman 
primates but are less pronounced in rodent models used for pre-clinical testing of 
vectors. The chronic host response continues for several weeks to several months 
after Ad administration. During this time, cells initially expressing low levels of 
viral genes and transgene products are recognized and eliminated by cytotoxic T 
cells (Schowalter, D.B. et al 1999; Tripathy, S.K., et al 1996). CD4+ T-cell-
dependent humoral immunity is responsible for the production of anti-adenoviral 
neutralizing antibodies, which rapidly clear the virus from the circulation and 
prevent successful gene transfer upon readministration (O'Riordan, C. et al 2002). 
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4. Strategies for circumvention of vector immunity 
 
In order to improve the clinical application of Ad vectors, it is most important to 
reduce or evade the vector immune response and enhance target cell transduction. 
Several approaches have been developed to meet these contradictory requirements 
for improving the efficacy of Ad vector-based gene transfer. 
 
4.1 Immunosupression or immunomodulation 
 
It has been shown that the use of immunosuppressive agents, such as cyclosporin, 
cyclophosphamide (Smith et al. 1996), deoxyspergualin (Kaplan et al. 1997), 
FK506, (Ilan et al. 1997) and CTLA4Ig (Guerette et al. 1996; Jooss et al. 1998), 
or transient depletion of CD4 lymphocytes using an anti-CD4 monoclonal 
antibody (Ye et al. 2000), use of anti-CD40 ligand antibody to block CD40-CD40 
ligand interactions (Chirmule et al. 2000), and oral tolerization to Ad proteins 
(Ilan et al. 1998) enhance the duration of transgene expression following systemic 
delivery of Ad vectors. These approaches help in inhibiting humoral, cell-
mediated, or both responses to Ad. Since macrophages play an important role in 
the induction of innate immune response following vector inoculation, depletion 
of macrophages and dendritic cells in the liver and spleen following 
administration of liposome-encapsulated dichloro-methylene-biphosphonate 
resulted in reduced cytokine production (Zhang et al. 2001). Short-term depletion 
of hepatic macrophages resulted in increased hepatic transgene expression and 
reduced transgene-specific humoral immune response following Ad vector 
inoculation in mice (Schiedner et al. 2003b). Similarly, depletion of alveolar 
macrophages prior to intratracheal administration of an Ad vector improved 
vector transduction and persistence in both immunocompetent and 
immunodeficient mice (Worgall et al. 1997). The use of immunosuppressive 
agents or depletion of macrophages will not be preferred in clinical cases due to 
the inherent toxicity of such strategies. Nevertheless, these studies have 
demonstrated the feasibility of manipulation of the host innate immune response 
 - 28 - 
against Ad vectors to allow increased vector survival and prolonged transgene 
expression. 
4.2 Altering native Ad vector and cell surface receptor interactions 
 
Ad5 attachment to a susceptible cell occurs via the interaction between the Ad 
fiber knob and cosackievirus adenovirus receptor (CAR) on the host cell 
membrane (Bergelson et al. 1997; Tomko et al. 1997). CAR is a member of the 
immunoglobulin superfamily and serves as a high-affinity receptor for Ad in 
families A, C, D, E, and F but not B. In addition, major histocompatibility (MHC) 
class I α2 domain (Hong et al. 1997), heparin sulphate glycosaminoglycan (Smith 
et al. 2003) or sialic acid saccharide (Arnberg et al. 2000) may also serve as the 
primary receptor for Ad. 
In addition to these primary receptors, host cell integrins serve as co-receptors for 
Ad entry (Wickham et al. 1993). The Ad penton base protein interacts with 
vitronectin-binding integrins, specifically αvβ3 and αvβ5, for virus uptake 
(Wickham et al. 1993). This process is facilitated by the arginine-glycine-
asparagine (RGD) motif of the penton base. Interestingly, the RGD motif is also 
found in a number of adhesion molecules that are known to interact with integrins 
(Bai et al. 1993). The interaction of Ad penton and αvβ1 integrins promotes actin 
cytoskeletal reorganization via activation of several signalling molecules (Li et al. 
2001). Binding of the Ad5 fiber knob to CAR receptor could be effectively 
prevented with a knob specific antibody. For targeting Ad5 vectors to receptors 
other than CAR, knob-specific neutralizing antibody could be complexed either to 
a specific ligand or a receptor-specific antibody (Bilbao et al. 1998) (Fig. 7). This 
complex molecule will efficiently bind Ad knob on one side and a specific 
receptor on the other side. With this technology, a wide variety of HAd5 vectors 
have been successfully targeted to a number of receptors including folate, 
epidermal growth factor, fibroblast growth factor, epithelial cell adhesion 
molecule (EpCAM), tumor-associated glycoprotein (TAG)-67, and CD40 (Bilbao 
et al. 1998).  These modified vectors should be preferentially taken up by the 
specific cells. 
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Figure 7 Some of the strategies for designing targeted adenoviral (Ad) 
vectors: A) Binding of adenovirus to cells via the knob domain of the fiber to 
CAR. B) Adenovirus complexed with an anti-knob antibody fails to bind to CAR. 
C) Conjugation of a specific ligand to the anti-knob antibody would allow virus 
binding to the targeted receptor on the cell surface. D) Conjugation of antireceptor 
antibody to anti-knob antibody would target the Ad vector to the specific receptor 
on the cell surface. 
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These modified vectors should be preferentially taken up by the specific cells. 
Ad5 fiber knob has been shown to induce dendritic cells activation and maturation 
(Molinier-Frenkel et al. 2003). Virus-induced maturation of dendritic cells was 
significantly reduced when knobless Ad particles were incubated with immature 
dendritic cells. Therefore, fiber knob modifications to incorporate cellular ligands 
with novel cell-binding capacity might confer targeting and decrease vector 
immunogenicity. Ad fiber and CAR interactions are considered important for 
preferential hepatic sequestration of Ad vectors following intravenous delivery. 
Uptake of Ad vectors by hepatocytes and Kupffer cells lead to an increase in 
cytokine and chemokine mRNA expression, and subsequently an enhanced innate 
immune response (Schoggins et al. 2005). 
Fiber-pseudotyped Ad vectors were found to induce significantly lower innate 
immune response following systemic delivery, highlighting the importance of 
fiber-modification in Ad gene delivery. Similarly, immunogenicity of a chimeric 
vector containing Ad35 capsid and Ad5 fiber knob was enhanced indicating a 
potential role of the fiber knob in the immunogenicity of Ad5 vectors (Nanda et 
al. 2005). It is very important to mention here that, despite a lower innate immune 
response, adaptive cellular and humoral responses were not affected by fiber 
modification. Since virus neutralizing antibodies are primarily directed to Ad 
hexon (Ostapchuk et al. 2001), it is anticipated that modification of hexon will 
evade vector immunity. 
Targeting of Ad vectors could also be achieved by fusing the extracellular domain 
of CAR to peptide-targeting ligands (Kim et al. 2002). Genetic targeting of Ad 
vectors by engineering small peptides into the Ad fiber (Aoki et al. 2001), protein 
IX ( Zakhartchouk et al. 2004) or by replacing the fiber protein with the phage T4 
fibritin (Krasnykh et al. 2001) has been also demonstrated, but the size of the 
peptide appears to be a limitation. Similarly, the use of bifunctional polyethylene 
glycol molecules is useful in ablating the vector tropism by CAR-mediated 
interaction and providing specific vector targeting by incorporating a ligand for a 
particular receptor (Lanciotti et al. 2003). 
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4.3 Vector microencapsulation 
 
The use of polyethylene glycol-cationic lipid to coat Ad vectors (Chillon et al. 
1998) and poly (lactic-glycolic) acid (PLGA) copolymer encapsulation (Beer et 
al. 1998) has also been shown to elude virus-neutralizing antibodies. Sodium 
alginate-based biodegradable microparticles have been shown to encapsulate 
purified protein, bacteria, DNA or viruses and can be delivered to the animals by 
various routes of inoculation (Mittal et al. 2000). Since alginate microspheres are 
biodegradable and no harsh treatments or organic solvents are used in the process 
of their synthesis, the viability of Ad vectors in these microparticles is usually 
very high. Encapsulation of an Ad5 vector into alginate microparticles could 
effectively evade the vector-specific immune response (Sailaja et al. 2002). More 
than 70% of alginate microspheres are approximately 5–10 µm in size, and 
therefore, it is expected that majority of them will be taken up by macrophages 
and dendritic cells (Lomotan et al. 1997). It appears that alginate microspheres 
may be an attractive delivery system to target macrophages and dendritic cells, 
but there is a need to study the role of these microparticles in modulating the 
immune response through macrophages and dendritic cells. 
Use of bilamellar cationic liposomes to encapsulate Ad vectors also provided 
protection from preexisting humoral immune responses (Yotnda et al. 2002). 
Similarly, microsphere-liposome complexes gard Ad vectors from neutralizing 
antibody responses and are capable of effectively transducing cells leading to 
successful transgene expression (Steel et al. 2004). It seems that transgene 
expression levels by encapsulated vectors are usually lower (approximately 50–
70%) than those of unencapsulated vector both in the naïve and vector primed 
animals (Sailaja et al. 2002). It may be due to slow release of the vector from 
microparticles over time that will also prolong the duration of transgene 
expression. 
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4.4 Use of alternate had serotypes (serotype switching) 
 
Since more than 50 Ad serotypes exist, and the neutralizing humoral immune 
response to Ad is serotype-specific, another strategy to overcome Ad vector 
immune response could be serotype switching in vector construction (Parks et al. 
1999). Subgroup B Ad, such as Ad3, Ad11, and Ad35, have been shown to utilize 
the membrane cofactor protein CD46 as an attachment receptor 
(Gaggar et al. 2003; Segerman et al. 2003; Sirena et al. 2004). This particular 
feature makes these viruses attractive for targeting cell types that are refractory to 
HAd5 vectors that are primarily dependent on CAR-mediated internalization. Low 
seroprevalence of Ad11 and Ad35 makes them promising vectors for in vivo 
applications. Replication-defective Ad35 vectors efficiently transduced human 
cells and eluded preexisting Ad immunity (Gao et al. 2003). Similarly, Ad11 
based replication-defective vectors have shown expanded tropism. Ad35 based 
replication-defective vector vaccines evaded preexisting Ad5 immunity in mice 
(Barouch et al. 2004) as well as in rhesus monkeys (Shiver et al. 2004). 
 
4.5 Use of Helper-Dependent Ad (HD-Ad) Vectors 
 
HD-Ad vectors are constructed by removing all coding sequences of the Ad 
genome except the packaging sequence and inverted terminal repeats, thereby 
eliminating the problem of residual viral gene expression associated with E1/E3-
deleted Ad vectors (Mitani et al. 1995; Parks et al. 1996). Initial studies showed 
that HD-Ad vectors elicited limited cell-mediated immune response, had high 
cloning capacity, and produced long-term gene expression in both naïve small 
laboratory animals (Morsy et al. 1998; Schiedner et al. 1998), and nonhuman 
primates (Morral et al.1999) without causing significant liver damage and 
toxicity. Systemic delivery of HD-Ad vectors has been shown to provide strong 
transgene expression for prolonged period with minimal toxicity in the baboon, 
mouse, or canine model (Brown et al. 2004; Morral et al. 1999). 
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HD-Ad vectors also induce vector-specific immune response similar to that 
generated by E1-deleted Ad (Roth et al. 2002). Systemic administration of HD-Ad 
vectors in baboons also leads to acute toxicity accompanied by activation of the 
innate response in a dose-dependent manner (Brunetti-Pierri et al. 2004) 
indicating that vector-mediated acute toxicity is independent of viral gene 
expression. Sequential delivery of different HD-Ad vector serotypes circumvented 
the humoral response to the virus (Morral et al. 1999) suggesting that long-term 
transgene expression was possible by sequential delivery of HD-Ad vectors of 
different serotypes. However, acute toxicity due to vector is not prevented or 
reduced, implying the importance of the viral capsid components in vector 
toxicity.  
 
4.6 Use of Nonhuman Ad Vectors 
 
Since Ad viruses are species-specific, nonhuman Ad are expected to be no 
prevalent in humans, and therefore, they evade preexisting Ad immunity. In order 
to extend the range of Ad vectors that could be used to evade Ad neutralizing 
immune response, a number of nonhuman Ad such as bovine Ad type 3 (BAd3) 
(van Olphen et al. 2002), canine Ad type 2 (Hemminki et al. 2003), ovine Ad 
(Hofmann et al. 1999), chimpanzee Ad (Farina et al. 2001), and porcine Ad type 3 
(Bangari et al. 2004) were exploited for vector construction. It has been shown 
that nonhuman Ad vectors infect human cells in culture leading to expression of 
the transgene (Bangari et al. 2004; Bangari et al. 2005). Since HAd5-, BAd3- and 
PAd3-specific neutralizing antibodies do not cross-neutralize (Moffatt et al. 
2000), it is expected that sequential administration of Ad5, BAd3 and PAd3 
would effectively evade the vector specific neutralizing immune response. The 
sera of mice immunized with Ad serotypes 2, 4, 5, 7, and 12 did not neutralize 
chimpanzee Ad (Farina et al. 2001) indicating the utility of such vectors in 
evading Ad preexisting immunity. Following the decline in transgene expression 
to background levels, readministration of the vector is necessary to maintain 
therapeutic levels of transgene expression; it seems that sequential administration 
of nonhuman Ad vectors could provide that opportunity. 
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5. PEGylation of adenoviral vectors 
 
Another approach to circumvent both cellular and humoral immune responses 
generated against Ad is biochemical modification of viral capsid proteins with 
non-toxic materials to shield the virus from the immune system. Covalent 
modification of biological molecules with functionalized poly(ethylene glycol) 
(PEG) has been studied since the late 1970s. Poly (ethylene) glycol has a low 
toxicity profile, does not have immunogenic properties and has been approved by 
the Federal Food and Drug Administration (FDA) for use in foods, cosmetics and 
pharmaceuticals including parenteral, topical, rectal and nasal formulations 
(Working, P.K., et al 1997). 
Several PEGylated products have received FDA approval within the last decade: 
adenosine deaminase (Adagen, Enzon), L-asparaginase (Oncaspar, Enzon), 
staphylokinase (PEG-SAK, Thrombogenics), interleukin α-2a (PEGASYS, 
Roche), interleukin α-2b (PEG-INTRON, Schering-Plough) and hemoglobin 
(Hemospan, Sangart). In most cases, these modified proteins have improved 
therapeutic efficacy with enhanced circulation half-life in vivo, enhanced 
solubility, and improved in vivo bioactivity. This technology has specifically been 
employed to protect therapeutic proteins and enzymes from neutralization in 
patients that must receive them as a chronic therapy (Scott, M.D., Murad, K.L., 
1998). 
Several groups have shown that administration of several doses of a PEGylated 
antigen induces a state of tolerance against the native antigen in 
immunocompetent animals. Ito et al. found that animals dosed with a series of six 
doses of PEGylated hen egg lysozyme (HEL) and rechallenged with six additional 
doses of unmodified HEL failed to produce detectable levels of anti-HEL IgG 
antibodies (Ito, H.O., 1998). So et al. also found that immunization of animals 
with PEGylated HEL effectively blunted the T cell mediated immune response 
against the native antigen (So, T., et al 1999). Further studies suggest that the 
extent by which the molecule is covered by PEG dictates the level of 
immunological tolerance to the antigen. Others have shown that increasing the 
molecular weight and branching of the functionalized PEG molecules also 
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effectively blunts the immune response against the native antigen in some 
instances (Caliceti, P., et al 1999). Mechanistic studies by Sehon and others 
suggest that the immunosuppression induced by PEG-antigen conjugates can be 
attributed to the production of antigen-specific suppressor T cells and by 
suppressor factors produced by these cells which in turn reduce the production of 
antigen-specific T and B cells (Sehon, A.H., Carl Prausnitz, 1991). 
5.1 Preliminary studies  
 
A method for the rapid conjugation of functionalized monomethoxypoly(ethylene) 
glycol (MPEG) activated by either tresyl chloride (TMPEG), succinimidyl 
succinate (SSPEG) or cyanuric chloride (CCPEG) to free lysine groups on the 
capsid proteins of E1/E3 deleted recombinant Ad vectors has been established in 
Maria Croyle laboratory . This process is simple to perform, is complete within 2-
3 hours and does not compromise the transduction efficiency of the virus (Fig. 8). 
This effect is probably due to the new physical properties of the PEGylated virus. 
PEGylation significantly reduced the negative surface charge of the virus capsid, 
which could promote non-specific interaction with the cell surface (Croyle, M.A., 
et al 2000). This modification also increased the partition coefficient of the virus, 
which would allow it to indiscreetly partition though cell membranes. While 
enhanced transduction efficiency could be an added benefit of PEGylation, it 
raises some additional issues about these new vectors. Conjugation of high 
molecular weight PEGs to various biomolecules can extend residence time in the 
circulation from minutes to days. This effect, in combination with a general 
increase in transduction efficiency could promote efficient transduction of tissue 
for which the vector was not intended. It is also unclear how enhanced circulation 
times of adenoviral vectors will affect the overall health of the patient. 
It has been also found that humoral and cellular immune responses were reduced 
in immunocompetent animals after a single intravenous dose of the modified 
vectors (Fig. 9). Th1 (IFN-γ and IL-2) and Th2 (IL-10) responses were observed 
in splenocytes from mice that received the native virus as evidenced by the 
stimulated production of subtype specific cytokine. Th1 responses were 
significantly reduced in samples from animals given PEGylated viruses.  
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Figure 8 Transduction Efficiency of PEGylated Ad in Mouse Liver: C57BL/6 
mice were injected intravenously (5x1011 vp/kg) with either unmodified (native) 
or PEGylated Ad encoded with the betagalactosidase transgene. Four days after 
injection, animals were necropsied and gene expression assessed in liver 
homogenates by a beta-galactosidase ELISA. Data reflect the average values from 
10 mice/treatment group. Error bars reflect the standard error of the mean of the 
data. MPEG – virus formulated with inactivated PEG included in the conjugation 
reactions but which is not linked to capsid proteins. 
 
 
 
 
 
Figure 9 PEGylation of adenoviral capsid proteins reduces the cellular and 
humoral response against the virus: A) Spleen cells were obtained from mice 
10 days after intravenous administration of PEGylated virus, unmodified 
adenovirus (native Ad) or unmodified virus formulated with 0.1% unactivated 
PEG (MPEG) at a dose of  5x1011 vp/kg particles/kg and assessed for adenovirus-
specific CTL responses when cultured with targets infected with the native virus 
by a chromium release assay. B) Anti-adenovirus neutralizing antibody levels 
measured in serum of mice 30 days after administration. Data are the average 
results from ten animals per treatment group studied in two separate experiments. 
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SSPEG and TMPEG preparations stimulated Th2 type responses. Splenocytes 
from animals given these vectors produced IL-10 levels twice that of animals 
given unmodified virus. In each analysis,  samples from animals that received a 
dose of unmodified virus in a formulation of PBS and 1% unactivated 
poly(ethylene) glycol (MPEG) generated responses similar to that seen with 
unmodified virus, indicating that PEG alone does not effect the immune response 
generated against adenoviral vectors independent of its modification of capsid. 
Mitigation of the immune response was the driving force for the development of 
PEGylated Ad vectors. After reviewing their immunological and physical stability 
profiles, vectors modified with the SSPEG chemistry were selected for additional 
studies to determine how this modification affected the acute phase of the innate 
immune response. In this study, C57BL/6 mice were given a single intravenous 
dose of 4 x 1012 particles/kg of either an unmodified E1/E3 deleted Ad expressing 
beta-galactosidase, an unmodified HD-Ad expressing the same transgene or 
PEGylated versions of each vector. Similar levels of transgene expression were 
found in all treatment groups. Despite this fact, PEGylation significantly reduced 
IL-6 levels in animals treated with the E1/E3 deleted vector by a factor of 4 and 
with the HD vector by a factor of 2 (Fig. 10). IL-12 production was reduced by a 
factor of 3 in animals treated with the modified E1/E3 deleted virus (Figure 10B). 
A similar drop was detected in animals treated with PEGylated HD Ad. 
PEGylation of each vector reduced TNF-α levels to baseline levels (Figure 10C). 
Other biochemical markers suggest that PEGylation may adequately dampen the 
innate response in a manner that reduces vector-induced tissue damage, 
coagulopathy and inflammation. It has been measure serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels as markers 
of tissue and liver damage and platelet counts as a marker for coagulopathy 
associated with vector administration. Even though each vector produced similar 
levels of gene expression, elevated serum transaminases with respect to saline 
controls were only detected in animals treated with the unmodified (native) E1/E3 
deleted Ad (Table 2). AST and ALT levels of animals treated with the PEGylated 
vectors fell within the normal range for C57BL/6 mice (Quimby, F.W., 1999). 
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Figure 10 PEGylation of recombinant Ad reduces serum levels of pro- 
inflammatory cytokines: Serum levels of IL- 6 (A), IL-12 (B) and TNF-alpha 
(C) were assessed from serum samples taken from C57BL/6 mice 6 hours after 
systemic administration of a single dose of 4x1012 particles/kg of either 
unmodified E1/E3 deleted Ad expressing the beta-galactosidase transgene 
(E1/E3), unmodified helper-dependent adenovirus Ad-SRα-βGEO (HD), or the 
PEGylated versions of each virus (PEGE1/ E3, PEG-HD). Data reflect average 
values + the standard error of the mean for five mice from each treatment group. 
 
 
 
Table 2 Serum transaminase levels of mice after systemic administration of 
unmodified and PEGylated Adenoviruses: Saline controls were bled 3 and 7 
days after treatment in the same manner as animals dosed with virus. Data 
represent the mean + standard error of 4 mice per treatment group. AST, aspartate 
transaminase; ALT, alanine transaminase; U/L, units per liter. **p = 0.001, *p = 
0.01. 
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Three days after vector administration, a significant drop in platelet count from 
was detected in animals treated with unmodified HD-Ad, which resolved to 
baseline levels 4 days later (Fig. 11). Animals treated with the PEGylated vector 
did not experience a drop in platelet count 3 days after vector administration. 
Platelet counts from this group were not statistically different than those from 
animals treated with a saline bolus and remained unchanged throughout the 
remainder of the study. Results were similar for the E1/E3 deleted vectors. 
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Figure 11 PEGylation of helper-dependent adenovirus prevents vector-
induced thrombocytopenia after systemic delivery: Fourteen days prior to 
vector administration, baseline platelet counts were determined (t=0). Mice were 
dosed with either 8x1010 viral particles of unmodified (HD) or PEGylated (PEG-
HD) Ad-SRα β-GEO or 100 microliters of saline (PBS, vehicle control). At each 
timepoint, mice were terminally bled and half the blood collected in tubes treated 
with sodium citrate for platelet analysis. Data reflect average values + the 
standard error of the mean for five mice from each treatment group. 
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CHAPTER II 
 
MATERIALS AND METHODS 
1. HD∆28E4LacZ production  
1.1 Helper virus  
 
The helper virus (HV) using in this work, AdNG163R-2, is a first generation 
adenoviral vector  that contains a reverse orientation ψ (with respect to the HDAd) 
flanked by loxP sites so that it is excised in Cre-expressing cells to render the HV 
genome unpackageable (Donna Palmer and Philip Ng,  2003) . Therefore, 
AdNG163R-2 contains a DNA stuffer, composed of noncontiguous λ DNA 
segments with no intact coding sequences, into the wild-type E3 region;   the HV 
have a large genome size (37.2 kb) so that maximum separation from HDAds 
(designed to be ~29 kb) can be achieved if necessary because a common and 
successful strategy to minimize HV contamination is physical separation from the 
HDAd by CsCl ultracentrifugation based on differences in their genome sizes 
(Sakhuja, K., et al. 2003).  
 
1.2 Producer cell line 116  
 
Cre-expressing producer cells (116) derive from 293N3S cells (Graham, F. L. 
1987), a 293 derivative capable of both adherent and suspension growth. 116 were 
generated by transfecting 293N3S cells with pNG159, a plasmid that contains the 
Cre-ricombinase and hygromycin-resistance coding sequences, separated by the 
encephalomyocarditis virus internal ribosome entry site.  
Monolayer of 116 cells was grown in MEM (Life Technologies) supplemented 
with 10% FBS (Invitrogen) and 50 µg/ml hygromycin (Sigma). Joklik’s modified 
MEM (Biowittaker) supplemented with 10% FBS and 50 µg/ml hygromycin was 
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used to grow 116 cells in suspension. Suspension 116 cells were grown in spinner 
flasks (Bellco) at 37°C on a magnetic stir plate. 
 
 
 
1.3 HD∆28E4LacZ rescue, amplification, and large-scale production 
 
 
HD∆28E4LacZ was rescued (serial passage P0) by transfecting a 60-mm dish of 
116 cells at ~80% confluency with 20 µg of PmeI-digested p∆28E4LacZ 
followed, the next day, by infection with 1000 vp/cell of AdNG163R-2. 
HD∆28E4LacZ was amplified by serial coinfections of 60-mm dishes of 116 cells 
at ~90% confluency with 10% of the crude lysate from the previous passage and 
200 vp\cell of AdNG163R-2  for serial passages 1, 2, 3 (P1, P2, P3). For P4, two 
150-mm dish of 116 cells at ~ 90% confluency were coinfected with 10% of the 
crude serial passage 3 lysate and 200 vp/ cell of  AdNG163R-2. All serial 
passages were harvested 48 h postcoinfection for use as inoculum for the 
subsequent passage after one freeze–thaw. 24 h after the infection every 
amplification passage was controlled by 5-bromo-4-chloro-3-indolyl β-D-
galactoside (X-Gal) staining.  
Large-scale HDAd production was performed as follows: 3 liters of 116 cells at 
3–4 x 105 cells/ml was harvested by centrifugation and resuspended in 5% volume 
conditioned medium and coinfected with 100% of the crude lysate from the 150-
mm dish of serial passage 4 and 200 vp/cell of AdNG163R-2. Virus adsorption 
was performed at 37°C on a magnetic stir plate for 2 h, after which medium (25% 
conditioned and 75% fresh Joklik’s MEM supplemented with 5% FBS and 25 
mM HEPES) was added to a final volume of 2 liters. Coinfected cells were 
harvested 48 h later for lysis and resuspended in TM solution (Tris HCl pH 8 1M 
and MgCl2 1M)  
Rescue, amplification, and large-scale production of HDAd are summarized in 
figure 12. 
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Figure 12 HDAd rescue, amplification, and large-scale production: Overview 
of the rescue (P0), amplification (P1 to P4), and large-scale production (P5) of 
HDAd. The entire process beginning with vector rescue (P0) to the final purified 
HDAd takes less than 2 weeks. 
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1.4 HD∆28E4LacZ purification  
 
The harvested cells were lised by three freeze-thaw cycles and were incubated 
with MgCl2 2M and DNase for 1 h at 37°C. After incubation the cellular debris 
was spinned   down and the lysate was subjected to ultracentrifugation on a 
continuous CsCl gradient with a Beckman SW41 rotor (35,000 rpm for 2 hr at 
4°C). The upper band, which contains virions, was eliminated and a second 
ultracentrifugation on a continuous CsCl gradient (35,000 rpm for 18 hr at 4°C) 
was performed.  The harvested vector was dialyzed  in a TM ( Tris HCl pH 8 1M 
and MgCl2 1M ) and was stored at -80° C. Vector concentration (particle number) 
was determined by UV spectrophotometric analysis at 260 nm: OD260 x 50 x 1012 
vp\ml. 
 
1.5 Southern analysis for helper virus contamination of 
HD∆28E4LacZ 
 
To analyze viral DNA for helper contamination, a fraction of 50 µl was incubated 
with 0.5 mg of proteinase K per ml in 10 mM Tris HCl, pH 7.5/10 mM 
EDTA/0.5% SDS at 37° C overnight. DNA was prepared by phenol/chloroform 
extraction and ethanol precipitation. The vector HD∆28E4LacZ, the helper virus 
AdNG163R-2 and the plasmid p∆28E4LacZ were  digested  with PstI and PmeI 
and fractionated on a 1,2 % agarose gel  and transferred to a nylon membrane 
(GeneScreen- Plus; NEN) using a slot blot apparatus (Minifold II; Schleicher). 
The membrane was hybridized using a probe designed on the ITRs of 
p∆28E4LacZ and prepared by PCR (Polymerase chain reaction) at this condition: 
Initialization step: 94°C for 10 minutes; Denaturation step :94°C for 30 seconds ; 
Annealing step: 58° for 30 seconds; Extension/elongation step: 72° for 30 
seconds; Final elongation: 72° for 3 minutes; Final hold: 4°C for indefinite time. 
The hybridization temperature was of 60°C and the hybridization buffer 
composed of 5x SSC, 0, 1% SDS, 5% dextran sulphate and 100 µg/ml salmon 
sperm. The washing were performed at 55°C with a solution of 0, 2% SSC and 0, 
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1% SDS. The autoradiography was performed with ECL Plus system 
(Amersham). 
 
1.6 HD∆28E4LacZ PEGylation 
 
Aliquots of virus were desalted on Econo-Pac 10DG disposable chromatography 
columns (Bio-Rad, Hercules, CA) and equilibrated with the respective buffer for 
optimal conjugation.  Viral concentrations were determined by UV 
spectrophotometric analysis at 260 nm. Transduction titer (LacZ-forming units or 
LFU) was determined by limiting dilution infections of 116 cells.  The protein 
content of viral preparation was determined by a microplate assay with Bio-Rad 
DC Protein assay reagents and bovine serum albumin as a standard (Bio-Rad). In 
total, 10 mg of monomethoxypoly (ethylene) glycol activated by succinimidyl 
succinate (SSPEG, mw 5000, Sigma-Aldrich) was added for each microgram of 
protein present in the preparation. Conjugation reactions were performed at 25° C 
with gentle agitation. Reactions were stopped by addition of a 10-fold excess of 
L-lysine (Sigma-Aldrich) with respect to the amount of PEG added. Unreacted 
PEG, excess lysine, and reaction by products were eliminated by buffer exchange 
over a second Econo-Pac 10DG disposable chromatography column (Bio-Rad) 
equilibrated with 100 mM potassium phosphate-buffered saline (pH 7.4). A 
separate aliquot of virus was treated and processed in the absence of SSPEG in the 
same manner as the conjugated virus and served as the unPEGylated control. 
 
1.7 Characterization of PEGylated HD-Ad vectors: capillary zone 
electrophoresis 
 
PEGylated and unPEGylated adenoviral vectors were characterized by capillary 
zone electrophoresis using a Beckman PACE 5000 system (Beckman Coulter) 
with an untreated 50 mm (ID) x 27 cm capillary. The temperature of the capillary 
was controlled at 221C. A preliminary 2 min wash in 1 N NaOH followed by a 2-
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min wash in nanopure water and a third wash in running buffer (20 mM sodium 
phosphate, pH 7.0, 5 mM sodium chloride) were performed prior to sample 
analysis. A voltage of 17 kV was used for the separations and the detector signal 
at 214 nm was recorded and processed by the PACE station software package. 
 
2. Animal studies  
2.1 Biochemical analysis 
 
Four male baboons (Papioi sp., 6-7 kg) had a 22-gauge catheter placed in the left 
cephalic vein for sample collection and administration of virus. Blood samples 
were taken prior to vector administration for blood cell counts (PT, aPTT, 
platelets, WBC, neutrophilis) and blood chemistry analysis (ALT, LDH) to 
establish baseline levels. Animals received one of two doses (5x1011vp/kg and 
3x1012 vp/kg) of either an unmodified or PEGylated HD-Ad expressing beta-
galactosidase. Animals were sedated with ketamine (10 mg/ml) prior to vector 
administration. Viruses were infused over 2-3 minutes and were followed by 
flushing the line with sterile saline. 
Blood samples (7 ml) were taken at various time points (1, 3, 6, 24, 48, 72 and 96 
hours). Two milliliters were used for cytokine analysis and DNA extraction. 
Cytokine levels (IL-6, IL-12, TNF-α) were determined with commercially 
available ELISA kits (Biosource International, Camarillo, CA). Viral DNA was 
isolated from tissues using DNeasy Tissue kits (Qiagen) according to the 
manufacture’s protocol and DNA concentration and purity were determined 
spectrophotometrically. 4 milliliters were used to determine blood cell counts (PT, 
aPTT, platelets, WBC, neutrophilis) and blood chemistries. Urine was collected at 
each time point via a catheter inserted in the bladder and feces will be collected 
daily for DNA extraction to determine the amount and how long the virus is shed 
from treated animals. All chemical parameters were run by the folks  
in San Antonio.  
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2.2 Neutralization assay 
 
 
Antiadenovirus antibody titers of baboons immunized with unmodified HD-Ad 
were determined by incubating serum samples at 56° C for 30 min to inactivate 
complement followed by dilution in DMEM in two-fold increments starting from 
a 1:20. Each dilution (100 ml) was mixed with an aliquot of a standard stock of 
unmodified adenovirus expressing E. coli beta-galactosidase, incubated for 1 h at 
37°C, and applied to HeLa cells in 96-well plates (2x104 cells/well). In total, 100 
ml of DMEM supplemented with 20% FBS was then added to each well. Cells 
were incubated at 37°C for 24 h. Neutralizing antibody titers were calculated as 
the highest dilution at which 50% of the cells stained blue by visual inspection. 
 
 
2.3 X-gal histochemistry 
 
These animals were necropsied 96 hr after vector administration and the 
histochemistry was done by cryosectioning tissue in OCT and X-gal  
staining. The tissues were incubate for 3 hours at 37oC and then for 24 hours at 
room temperature. After the washing the sections were controstained using 
Nuclear Fast Red. 
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3. Real- Time PCR 
 
 
DNA was isolated from tissues using DNeasy Tissue kits (Qiagen) according to 
the protocol manufacture’s DNA was purified by minicolumns and quantified by 
spectroscopy. Adenoviral DNA content was determined using spectroscopy. Real-
time PCR was performed on the DNA in an Applied Biosystems Prism 7900HT 
sequence detection system with SDS 2.1 software. The parameters used were  95° 
C for 10 min, 95° for 10 seconds (45 cycles), 60° for 7 seconds (45 cycles) and 
72° for 20 seconds (45 cycles). Reactions were performed in triplicate with no 
template as controls. Amplifications were carried out in a total volume of 20 µl 
with SYBR Green PCR Master Mix (Applied Biosystems), 2 µl of DNA template, 
4 mM MgCl2, and 5 µM primers HD-Ad specific designed on packaging signal. 
Serial dilutions of plasmid p∆28E4LacZ were used as control. 
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CHAPTER III 
 
RESULTS 
1.  HD∆28E4LacZ production in 116 cell line  
 
The HDAd used in this study, HD∆28E4LacZ, contains an MCMV-LacZ 
expression cassette (Palmer and Ng, 2003).  Four preps of virus were produced in 
116 cell line that unlike 293Cre4 cells and other producer cells can also grow in 
suspension, rendering large-scale HDAd production significantly more efficient 
and simpler, as well as less costly and labor intensive. We coinfected 2 liters (for 
prep)  of passage 45  116 cells at 3–4 x 105 cells/ml with AdNG163R-2 and the 
crude serial passage 4  lysate from two  150-mm dish . 24 h after the infection 
every amplification passage was monitored by X-Gal staining (Fig. 13). Forty-
eight hours postcoinfection, we purified HD∆28E4LacZ by one step and two 
continuous CsCl gradients (Fig. 14). Spectrophotometric analysis revealed that 
we obtained a  for each total yield of ~1,5 x 1013 vp/ml  corresponding to a 
specific yield of 12,650 vp/cell and a titer of 9 x 1011 blue forming units/ml (BFU)  
as determined by X-gal staining following titration on 293 cells. To analyze 
HD∆28E4LacZ in detail, we extracted virion DNA from the step and two 
continuous CsCl gradients and digested it with ApaLI and PmeI. Agarose gel 
electrophoresis analysis revealed that the genomic structure of HD∆28E4LacZ 
was indistinguishable from that of the parental p∆28E4LacZ plasmid, except for 
the expected absence of the 2.5-kb ApaLI–PmeI fragment bearing the bacterial 
plasmid sequences present in pD28E4LacZ, suggesting the absence of vector 
DNA rearrangements (Fig. 15) . 
To determine the level of HV contamination, we performed Southern analysis 
with probe ITR to compare the intensities HD∆28E4LacZ band and an 
AdNG163R-2 band (Fig. 16). The results revealed the AdNG163R-2-specific 
band was undetectable in the virion DNA extracted from all CsCl gradients. 
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A                                                                     B 
            
 
 
C                                                                  D 
 
Figure 13 X-gal staining: 24 hours after each amplification passage, the vector 
amplification was monitored by X-gal staining until to all the cells were stained: 
this passage was used to infect two 150 mm dishes of 116. (A: P0; B:P1; C:P2: 
D:P3). 
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Figure14 HD-Ad purification on cesium chloride: An examples of 
HD28E4LacZ obtained from 3 liters of 116 cell using AdNG163R-2 as helper 
virus. The second continuous CsCl gradient is shown.  
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Figure 15 Analysis of HD-AdLacZ DNA:  DNA was extracted from the virions 
obtained from the two continuous CsCl gradients and digested with ApaLI. The 
structure of HDAdLacZ DNA is indistinguishable from that of the parental 
p∆28E4LacZ plasmid, except for the expected absence of the 2.5-kb ApaLI–PmeI 
fragment bearing the bacterial plasmid sequences present in p∆28E4LacZ. 
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Figure 16 Southern analyses to verify HV contamination: The vector 
HD∆28E4LacZ, the helper virus AdNG163R-2 and the plasmid p∆28E4LacZ 
were digested with PstI and PmeI. Using an ITR probe, the AdNG163R-2-specific 
band was undetectable in the virion DNA extracted from all CsCl gradients. 
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1.1HD∆28E4LacZ PEGylation 
 
The succinimidyl propionate group of the SPA-PEG molecule reacts with 
nucleophilic groups (mostly ε-amino groups of lysine) on proteins to form stable 
amide bonds. The rate of reaction depends on the concentration of PEG, as well as 
the length of reaction time, temperature, and pH. In Based upon previous 
experience with PEGylation of recombinant viral vectors, a 2 h reaction time was 
selected. Four separate lots of HD-Ad. The average titer of all HD-Ad 
prepaearations prior to PEGylation was 9 x 1011 BFU/ml. PEGylated preparations 
had an average titer comparable with titer of preparation preparations prior to 
PEGylation. The PEGylation reaction was monitored by capillary electrophoresis. 
Unmodified HD-Ad had a peak at 7.3 min (Peak C), and a similar peak (Peak D) 
had HD-Ad after the conjugation reaction without PEG.  The PEG-HD-Ad vector 
was detected as a single peak at 6.4 min (Peak B). A standard solution of free 
PEG produced a single peak at 4.8 min (Peak A) and was absent from the 
PEGylated preparation, indicating that free PEG was efficiently removed after the 
conjugation reaction (Fig. 17). 
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Figure 17 Representative capillary electropherograms: (A) monomethoxypoly 
(ethylene) glycol activated by succinimidyl succinate (10 mg/ml), (B) PEGylated 
HD-AdLacZ, (C) unmodified HD-AdLacZ and (D) HD-Ad after the conjugation 
reaction without PEG. Samples were diluted 1:2 with sample buffer (20 mM 
sodium phosphate buffer, pH7.0, 5 mM sodium chloride). Capillary length was 27 
cm. 
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2. Toxicity profiles of PEGylated HD-Ad 
 
2.1 Tissue damage 
 
Serum biochemical markers were measured at various times postinjection (0, 1, 3, 
6, 24, 48, 72 and 96 hours)   to assess tissue and liver damage of four baboons 
(Papioi sp., 6-7 kg)  sedated with ketamine and injected  in the left cephalic vein 
with two different doses of HD-Ad-LacZ and PEG HD-Ad-LacZ: 5x1011 vp/Kg 
and 3x1012 vp/Kg. Within the first hours after the administration, baboons treated 
with low and high doses of no PEGylated vector, underwent an increase in serum 
levels of serum aspartate aminotransferase (AST) and Lactate dehydrogenase 
(LDH), with levels that were two to three times higher in the high dose baboon 
respect to the low dose baboon.  The serum levels returned to within normal limits 
by 24 hr.  An increase of serum levels of AST and LDH was also observed within 
the first hours after the administration of baboons injected with low and high 
doses of PEG HD-Ad-LacZ but were one to two and three to five times lower 
compared to the values of animals treated with the respective dose of HD-Ad-
LacZ (Fig. 18).  
These results suggest that liver and tissue damage occurred rapidly after vector 
exposure. This was relatively mild and transient in the baboons treated with 
PEGylated vectors. 
2.2 Coagulopathy 
 
Markers for disseminated intravascular coagulation (DIC) were measured at 
various times postinjection. Within the first hours after the injection, prothrombin 
time (PT) of baboons treated with HD-Ad-LacZ increased from a baseline time, 
with higher levels in the high dose baboon, and back to baseline level by 24 hour. 
Serum levels of PT in each of baboons injected with modified vector increased 
not much in the first time to return quickly at normal values. The baboon treated 
with low dose of no modified vector, showed an increase of values of the 
activated partial thromboplastin time (aPTT) that decreased to a nearly normal 
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values in the subsequent hours, while in the high dose baboons the PPT rose, 
reaching the major peak at 24 hours and then underwent a rapid decrease. Serum 
levels of PPT in baboons injected with PEGylated vector, increased until to 24 
hours, and then decreased but kept values lower respect to the results reaching 
with baboons treated with unmodified vector (Fig. 19). 
At 3 hours after vector administration, a modest drop in platelet count was 
detected in the animal treated with low dose of unmodified HD-Ad; this value 
rose slightly within six hours, and then had a significant drop. Similar result 
showed the platelet count of the animal administred with low dose of PEG HD-
Ad-LacZ, with a major difference in the values in the first six hours. The platelet 
count in the high dose baboons treated with unmodified vectors was no different 
than those from animal treated with modified vector. In the first hours both 
animals showed a drastic drop in platelet count, but the values returned to baseline 
only for the baboon treated with PEGylated vector by 72 hours postinjection  
(Fig.20). These results provide evidence that systemic administration of HDAd 
resulted in DIC, with a decrease of platelets and increase of PT and PTT, while 
the PEGylation alleviates vector-induced thrombocytopenia after systemic 
administration and prevent the prolongation of coagulation time. 
 
2.3 Acute inflammation 
Several markers for activation of the acute inflammatory response were measured 
at various times postinjection. Similar to conditions of acute infection and 
inflammation, all baboons administred with unmodified vector showed a rapid 
increase in white blood cell counts (WBC) shortly after vector injection (Fig.21). 
In the first 6 hours   after injection, both baboons showed an increase of 
granulocytes, while the lymphocytes, after an initial decrease, increased and rise a 
major peak 48 hours after vector administration. For the animals treated with 
PEGylated vector, the WBC initially decreased, but then increased reaching the 
higher values at 6 hours; the values were lower in the high dose baboons. The 
granulocytes, for both animals injected with modified vector, increased within 3 
 - 58 - 
hours, while the lymphocytes decreased to increase between 24 and 72 hours 
(Fig.22).  
Serum samples were collected 6 h after administration of each vector and 
analyzed for interleukin 6 (IL-6), interleukin 12 (IL-12) and tumor necrosis factor 
(TNF-α), markers commonly associated with activation of the innate immune 
response against recombinant adenoviral vectors. A single 6 h time point was 
selected because, in a mouse model, these cytokines peak approximately 6 h after 
vector administration and rapidly decline to baseline values by 24 h.  
IL-6, IL-12, TNF-α increased rapidly after injection of vector in  animals treated 
with  HD-Ad-LacZ and were three, two and seven times higher in the baboons 
treated with high dose respect to the baboons administred with low dose. In the 
animal treated with low dose of PEGylated vector IL-6 and TNF-α were absent, 
while the values of IL-12 were lower compared with serum level of IL-12 in the 
baboons injected with unmodified vector. The baboons treated with high dose of  
PEG HD-Ad-LacZ, showed IL-6 and IL-12 secretion with values lower respect to 
the values of unmodified vectors, while TNF-α was absent (Fig.23). 
Taken together, these results suggest that an acute inflammatory response was 
provoked as a consequence of systemic unmodified vector administration, the 
severity of which appeared dose dependent but PEGylation may adequately 
dampen the innate response in a manner that reduces acute inflammation. 
 
2.4 In vivo performance of PEGylated HD-Ad 
X-Gal histochemistry was performed on tissues to determine the degree and 
distribution of vector transduction. There was a different transgene expression in 
vivo, indeed  histochemical liver section  of  baboons treated with 5x1011 vp/kg  of 
unmodified revealed that many hepatocytes stained positive for β-galactosidase  
but significantly more transduction was observed in  histochemical liver section  
of  baboons treated with low dose of PEGylated vector (Fig.24). 
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Figure 18 Serum levels of AST and LDH: The graphs shown serum levels of 
AST and LDH in the baboons treated with low and high dose of unmodified and 
modified vector. The tissue and liver damage was reduced in the baboons treated 
with PEGhilated vector. 
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Figure 19 Serum levels of PT and PTT:  The graphs shown serum levels of PT 
and PTT in the baboons treated with low and high dose of unmodified and 
modified vector. The prolongation of coagulation time was reduced in the 
baboons treated with PEGhilated vector. 
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Figure20. Platelet count: The graphs show the platelet count in the baboons 
treated with low and high dose of unmodified and modified vector. PEGylation of 
helper-dependent adenovirus prevents vector-induced thrombocytopenia after 
systemic delivery. 
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Figure 21 Serum levels of WBC: The graphs shown serum levels of WBC in the 
baboons treated with low and high dose of unmodified and modified vector. 
Similar to conditions of acute infection and inflammation, all baboons administred 
showed a rapid increase in WBC shortly after vector injection 
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Figure 22 Serum levels of granulocytes and lymphocytes: The graphs shown 
serum levels of granulocytes and lymphocytes in the baboons treated with low and 
high dose of unmodified and modified vector. However, the modified vector 
provoked a low acute toxicity. 
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Figure 23 Serum levels of proinflammatory citokynes: The graphs shown 
serum levels IL-6, IL-12, TNF-α in the baboons treated with low and high dose of 
unmodified and modified vector. PEGylation of recombinant Ad reduces serum 
levels of pro- inflammatory cytokines 
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Figure 24 LacZ staining of frozen liver section:  Liver section from baboons 
injected with (A) unmodified or (B) PEGylated HDAdLacZ, at 5 x10 11 vp/ were 
stained.  Surprisingly, the baboon treated with PEGylated vector showed more 
hepatic transduction respect to the baboon treated with the unmodified vector. 
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3.  Biodistribution of PEGylated vectors in vivo 
 
Four baboons were administered with two different doses of HD-AdLacZ and 
PEGHD-AdLacZ intravenously through cephalic vein injection. 96 hours later, 
the animals were sacrificed, various organs were harvested (liver, gonads, 
intestine, spleen, kidney, stomach, heart, pancreas, brain, lungs and skeletal 
muscle) and DNA was extracted to determined the levels of vector DNA (vector 
copy number/ng genomic DNA) by real-time PCR.  
The liver lobes showed different infectivity levels: the left median lobe (LML) 
and the right median lobe (RML) of baboons treated with low dose of unmodified 
vector were infected about sixty and seventy times more than the some lobes of 
baboons treated with PEGylated vector; in the left liver lobe and the right liver 
lobe of baboons administred with low dose of HD-AdLacZ was observed an 
infectivity about ten and thirty times higher respective to baboon injected with the 
some dose of PEG-HD-AdLacZ. The high dose of PEGylated vector didn’t 
present signs of infectivity in the liver lobes.  
Surprisingly, the infectivity in the spleen of baboons treated with low dose of 
modified vector was eight times higher compared to the infectivity in the same 
organ of all other animals (Fig.24) 
In the kidneys, the infectivity of modified and unmodified low dose vectors 
appeared to be higher than the infectivity of high dose vectors, but it is not very 
high.  
Finally, the lungs of baboons treated with low dose of unmodified vector, were 
infected two and one times more than those of the baboons injected with low dose 
of PEGylated vector.  The high dose of modified vector didn’t infect the lungs 
(Fig.25). Like to the kidney, the infectivity levels were very low.  
This data suggest that the virus infectivity was very poor in an independent dose 
manner.  
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Figure 24  Real-time PCR : The graphs show the vector infectivity in lobe of 
liver and in the spleen for the baboon treated with unmodified low dose of vector 
(17988), with modified   dose of vector (18167), with unmodified high dose of 
vector (20125), with modified low dose of vector (21585). 
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Figure 25  Real-time PCR : The graphs show the vector infectivity in  kidney 
and lung  for the baboon treated with unmodified low dose of vector (17988), with 
modified   dose of vector (18167), with unmodified high dose of vector (20125), 
with modified low dose of vector (21585) 
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CHAPTER IV 
 
DISCUSSION 
 
Gene therapy is the insertion of genes into an individual's cells and tissues to treat, 
especially hereditary disease in which a defective mutant allele is replaced with a 
functional one. In most gene therapy studies, a "normal" gene is inserted into the 
genome to replace an "abnormal," disease-causing gene, using viral or non viral 
vector to treat the pathology. 
Adenoviruses are robust vectors for in vivo gene delivery because of  some 
important reasons :  (a) many human and animal adenoviruses are non-pathogenic 
for their natural hosts, (b) a variety of both proliferating and quiescent cell types, 
such as epithelial cells, fibroblasts, hepatocytes, endothelial cells and stromal 
cells, can be infected with Ad vectors, (c) Ad vectors can be grown to very high 
titers that offer a means to infect a large number of target cells, and (d) 
replication-competent ((E3) –deleted vectors), conditional replication-competent 
(vectors in which E1A is under the control of a tissue- or cancer antigen-specific 
promoter), replication-defective (E1, E1 and E3, E2, E4, E2 and E4, or E1, E2 and 
E4-deleted vectors) and helper-dependent (vectors in which the majority of Ad 
genome is deleted) Ad vectors can easily be generated. While potent, Ad is 
limited by its immunogenicity and liver toxicity when delivered in high doses in 
rodents, in nonhuman primates and in humans.  
Scientists working on Ad vectors for gene  therapy learnt a bitter lesson on 
September 17, 1999, when 18-year-old Jesse Gelsinger died after receiving a very 
high dose (3.8 x 1013 particles) of Ad vector to treat  the ornithine 
transcarbamylase (OTC) disorder, a rare genetic defect in the liver that renders the 
body unable to clear ammonia from the bloodstream..  The death of the young 
patient, gives the biomedical community pause for thought, but it does not change 
the fact that gene therapy is a relevant and important area of investigation that is 
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ready for testing in carefully designed human trials. So, this tragedy and a number 
of subsequent animal inoculation studies demonstrated that higher vector doses 
invariably lead to hepatotoxicity and acute inflammatory response mainly due to 
activation of innate immunity. 
Significant improvement in the safety and efficacy of Ad-based vectors came with 
the development of helper-dependent adenoviral vectors, which are deleted of all 
viral coding sequences. HDAds retain the advantages of FGAds, including high-
efficiency in vivo transduction and high-level transgene expression. However, 
owing to the absence of viral gene expression in transduced cells, these HDAds 
are able to mediate high-level, long-term transgene expression in the absence of 
chronic toxicity. In addition, because the vector genome exists episomally in 
transduced cells, the risks of germ line transmission and insertional mutagenesis 
leading to oncogenic transformation are negligible. Moreover, the deletion of the 
viral sequences permits a large cloning capacity of ~37 kb, allowing for the 
delivery of whole genomic loci, multiple transgenes, and large cis-acting elements 
to enhance, prolong, and regulate transgene expression. 
The main problem with HD-Ad vectors are the helper virus contamination and the 
activation of innate immune response trigger by viral capsid proteins, but this  is 
lower the cellular immune response.   
Covalent attachment of polymers such as polyethylene glycol (PEG) to Ad capsid 
has been shown to curtail antibody-mediated virus neutralization. Such 
modifications are also expected to elude innate immunity since they will 
potentially mask the molecular patterns on the viral capsid with little or no effect 
on virus infectivity. Consistent with this, monomethoxypolyethylene glycol 
conjugation of Ad vector lead to reduced innate immunity and improved 
therapeutic index in mice when compared to unmodified Ad vectors. 
Based on these considerations, we decided to conduct a study to evaluate the 
toxicity and biodistribution of HD-Ad and PEG-HD-Ad in nonhuman primates. 
For the purpose we produced, a helper dependent adenoviral vector contains an 
MCMV-LacZ expression cassette (HD-Ad∆28E4LacZ). The preps of viruses 
were produced in 116 cell line that can also grow in suspension, rendering large-
scale HDAd production significantly more efficient and simpler, as well as less 
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costly and labor intensive. We amplified the vector by serial coinfections of 60-
mm dishes of 116 cells with 10% of the crude lysate from the previous passage 
and virus helper AdNG163R-2 for serial passages (P0 to P3). For P4, we 
coinfected 116 cells with 10% of the crude serial passage 3 lysate in two 150-mm 
dishes and performed large-scale HDAd production in 3 liters of 116 cells 
coinfected with 100% of the crude lysate from the 150-mm dish of serial passage 
4 and AdNG163R-2. 
Our system for producing HDAds represents an improvement over other methods 
in terms of simplicity and efficiency as well as vector yield and purity. However, 
it should be stressed that direct comparisons between different systems are 
difficult due to both fundamental differences in the component reagents (producer 
cell line, HV, and HDAd backbones) and especially the procedural variations used 
for HDAd production. So, we produced a virus with a safety and efficacy that can 
be used meaningful preclinical studies in large animal models and perhaps 
ultimately for clinical applications.  
After virus production we PEGylated a part of the vector using poly (ethylene 
glycol) and then we administred it at four baboons in two different doses of 
unmodified and PEGylated vector a low dose (5 x1011 vp/kg) and high dose (3x 
1012 vp/kg) determined the acute clinical, pathological, and biochemical 
consequences. 
Biochemical evidence of liver and tissue damage in the form of elevated levels of 
AST and LDH we observed in all animals treated, with higher levels in the animal 
administred with the unmodified vector, at the same time points postinjection.  
Indeed, although evidence of DIC we noted in all baboons, with prolongation of 
PT and aPTT, and decreases in platelets, these abnormalities were generally 
relatively mild and transient in the animals treated with PEGylated vector and 
more pronounced in the baboons’ administred with unmodified vector.  
All animals exhibited evidence of innate inflammatory immune response 
activation. We observed an elevation of IL-6, IL-12 and TNF-α, and we note that 
PEGylation significantly reduced cytokine production but did not ablate it. This 
may be due to the fact that the polymer did not completely cover the virus capsid. 
 - 72 - 
Our results show that the severity of HDAd-mediated acute toxicity is dose 
dependent but it can be reduced by PEGylated vectors. The Real -Time PCR data 
showed different organs infectivity with modified and unmodified vector: it is 
dose independent. 
So, we have found that combining PEGylation and HD-Ad technologies 
significantly reduces cytokine secretion, serum transaminases and alleviates 
vector-induced thrombocytopenia after systemic administration, leading to a 
significantly improved therapeutic index of adenoviral gene transfer. This 
suggests that PEGylation of HD-Ad vectors may be appropriate for their safe and 
efficient use in the clinic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 73 - 
BIBLIOGRAPHY 
 
 
Amalfitano, A., and Chamberlain, J.S. (1997). Isolation and characterization of 
packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and 
preterminal proteins: Implications for gene therapy. Gene Ther. 4, 258–263. 
 
Amalfitano, A., Hauser, M.A., Hu, H., Serra, D., Begy, C.R., and 
Chamberlain, J.S. (1998). Production and characterization of improved 
adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72, 926–933. 
 
Anderson, C. W., Young, M. E. & Flint, S. J. (1989). Characterization of the 
adenovirus 2 virion protein, mu. Virology 172, 506±512. 
 
Aoki Y, Hosaka S, Kawa S, Kiyosawa K. (2001)Potential tumor-targeting 
peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD 
motif. Cancer Gene Ther ;8:783–787. 
 
Arnberg N, Edlund K, Kidd AH, Wadell G. (2000)Adenovirus type 37 uses 
sialic acid as a cellular receptor. J Virol;74:42–48. 
 
Bai M, Harfe B, Freimuth P. (1993) Mutations that alter an Arg-Gly-Asp (RGD) 
sequence in the adenovirus type 2 penton base protein abolish its cell-rounding 
activity and delay virus reproduction in flat cells. J Virol;67:5198–5205. 
 
Bangari DS, Mittal SK. (2004) Porcine adenoviral vectors evade preexisting 
humoral immunity to adenoviruses and efficiently infect both human and murine 
cells in culture. Virus Res ;105:127–136. 
 
Bangari DS, Shukla S, Mittal SK. (2005 )Comparative transduction efficiencies 
of human and nonhuman adenoviral vectors in human, murine, bovine, and 
porcine cells in culture. Biochem Biophys Res Commun ;327:960–966.  
 
Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, 
Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, 
Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, 
Goudsmit J.(2004) Immunogenicity of recombinant adenovirus serotype 35 
vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol ;172:6290–
6297.  
 
Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson 
BL.(1998) Poly (lactic-glycolic) acid copolymer encapsulation of recombinant 
adenovirus reduces immunogenicity in vivo. Gene Ther ;5:740–746. 
 
Ben-Israel, H., and Kleinberger, T. (2002). Adenovirus and cell cycle control. 
Front. Biosci. 7, dl369–d1395. 
 - 74 - 
Bennett, E.M., Bennink, J.R., Yewdell, J.W., and Brodsky, F.M. (1999). 
Cutting edge: Adenovirus E19 has two mechanisms for affecting class I MHC 
expression. J. Immunol. 162, 5049–5052. 
 
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, 
Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997). Isolation of a 
common receptor for Coxsackie B viruses and adenoviruses 2 and 5. 
Science;275:1320–1323. 
 
Berk, A.J. (1986). Adenovirus promoters and E1A transactivation. Annu. Rev. 
Genet. 20, 45–79. 
 
Bett, A.J., Prevec, L., and Graham, F.L. (1993). Packaging capacity and 
stability of human adenovirus type 5 vectors. J. Virol. 67, 5911–5921. 
 
Bilbao G, Gomez-Navarro J, Curiel DT.(1998) Targeted adenoviral vectors for 
cancer gene therapy. Adv Exp Med Biol;451:365–374 
 
Boom WH, Liano D, Abbas AK. Heterogeneity of helper/inducer T 
lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell 
clones on resting B lymphocytes. J Exp Med 1988;167:1350–63. 
 
Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D.(2004) 
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression 
for several months with minimal accompanying toxicity in a canine model of 
severe hemophilia A. Blood ;103:804–810.  
 
Bruder, J.T., Jie, T., Mcvey, D.L., and Kovesdi, I. (1997). Expression of gp19K 
increases the persistence of transgene expression from an adenovirus vector in the 
mouse lung and liver. J. Virol. 71, 7623–7628. 
 
Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng 
P.(2004) Acute toxicity after high-dose systemic injection of helper-dependent 
adenoviral vectors into nonhuman primates. Hum Gene Ther ;15:35–46. 
 
 
Caliceti, P., Veronese, F. M. and Jonak, Z.,(1999) Immunogenic and 
Tolerogenic Properties of Monomethoxypoly(ethylene glycol) Conjugated 
Proteins. Il Farmaco,  54: 430-437. 
 
Chattopadhyay, D., Ghosh, M.K., Mal, A., And Harter, M.L. (2001). 
Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged 
cells. J. Virol. 75, 9844–9856. 
 
Chen, P., Tian, J., Kovesdi, I., and Bruder, J.T. (1998). Interaction of the 
adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J. 
Biol. Chem. 273, 5815–5820. 
 - 75 - 
Cheshenko, N., Krougliak, N., Eisensmith, R.C., and Krougliak, V.A. (2001). 
A novel system for the production of fully deleted adenovirus vectors that does 
not require helper adenovirus. Gene Ther. 8, 846–854. 
 
Chillon M, Lee JH, Fasbender A, Welsh MJ.(1998) Adenovirus complexed 
with polyethylene glycol and cationic lipid is shielded from neutralizing 
antibodies in vitro. Gene Ther ;5:995–1002. 
 
Chinnadurai, G., Chinnadurai, S., and Brusca, J. (1979). Physical mapping of 
a large-plaque mutation of adenovirus type 2. J. Virol. 32, 623–628. 
 
Chirmule N, Propert K, Magosin S, et al.(1999) Immune responses to 
adenovirus and adeno-associated virus in humans. Gene Ther ;6:1574–83. 
 
Chirmule N, Raper SE, Burkly L, Thomas D, Tazelaar J, Hughes JV, Wilson 
JM (2000) Readministration of adenovirus vector in nonhuman primate lungs by 
blockade of CD40-CD40 ligand interactions. J Virol;74:3345–3352. 
 
Christ, M., Louis, B., Stoeckel, F., Dieterle, A., Grave, L., Dreyer, D., Kintz, 
J., Ali Hadji, D., Lusky, M. and Mehtali, M.,(2000) Modulation of the 
Inflammatory Properties and Hepatotoxicity of Recombinant Adenovirus Vectors 
by the Viral E4 Gene Products. Hum. Gene Ther. 2000. 11: 415-427. 
 
Clemens, P.R., Kochanek, S., Sunada, Y., Chan, S., Chen, H.H., Campbell, 
K.P., and Caskey, C.T. (1996). In vivo muscle gene transfer of full-length 
dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965–
972. 
 
Croyle MA, Chirmule N, Zhang Y, Wilson JM. (2002) PEGylation of E1- 
deleted adenovirus vectors allows significant gene expression on readministration 
to liver. Hum Gene Ther ; 13: 1887–1900. 
 
Croyle MA, Yu QC, Wilson JM. (2000) Development of a rapid method for the 
PEGylation of adenoviruses with enhanced transduction and improved stability 
under harsh storage conditions. Hum Gene Ther;  11:1721–1730. 
 
Dai, Y., Schwarz, E.M., Gu, D., Zhang, W.W., Sarvetnick, N., and Verma, 
I.M. (1995). Cellular and humoral immune responses to adenoviral vectors 
containing factor IX gene: Tolerization of factor IX and vector antigens allows for 
long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401–1405. 
 
De Geest BR, Van Linthout SA, Collen D. (2003) Humoral immune response in 
mice against a circulating antigen induced by adenoviral transfer is strictly 
dependent on expression in antigen-presenting cells. Blood;101:2551–6. 
 
Dobner, T., Horikoshi, N., Rubenwolf, S., and Shenk, T. (1996). Blockage by 
adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. 
Science 272, 1470–1473. 
 - 76 - 
Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, 
Ertl HC, Wilson JM.(2001) Replication-defective vector based on a chimpanzee 
adenovirus. J Virol ;75:11603–11613. 
 
Fields PA, Kowalczyk DW, Arruda VR, et al. (2000) Role of vector in 
activation of T cell subsets in immune responses against the secreted transgene 
product factor IX. Mol Ther;1:225–35. 
 
Finkelman FD, Holmes J, Katona IM, et al. (1990) Lymphokine control of in 
vivo immunoglobulin isotype selection. Annu Rev Immunol;8:303–33. 
 
Finnen, R.L., Biddle, J.F., And Flint, J. (2001). Truncation of the human 
adenovirus type 5 L4 33-kDa protein: Evidence for an essential role of the 
carboxy-terminus in the viral infectious cycle. Virology 289, 388–399. 
 
Fuchs, M., Gerber, J., Drapkin, R., Sif, S., Ikura, T., Ogryzko, V., Lane, 
W.S., Nakatani, Y., And Livingston, D.M. (2001). The p400 complex is an 
essential E1A transformation target. Cell 106, 297–307. 
 
Gaggar A, Shayakhmetov DM, Lieber A.(2003) CD46 is a cellular receptor for 
group B adenoviruses. Nat Med ;9:1408–1412.  
 
Gaggar, A., Shayakhmetov, D.M., and Lieber, A. (2003). CD46 is a cellular 
receptor for group B adenoviruses. Nat. Med. 9, 1408–1412. 
 
Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, 
Barratt-Boyes S, Gambetto A.(2003) Effects of a SARS-associated coronavirus 
vaccine in monkeys. Lancet ;362:1895–1896. 
 
Grable, M., And Hearing, P. (1990). Adenovirus type 5 packaging domain is 
composed of a repeated element that is functionally redundant. J. Virol. 64, 2047–
2056. 
 
Graham, F. L. (1987). Growth of 293 cells in suspension culture. J. Gen. Virol. 
68: 937–940. 
 
Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics 
of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. 
Virol. 36, 59–74. 
 
Guerette B, Vilquin JT, Gingras M, Gravel C, Wood KJ, Tremblay JP 
(1996). Prevention of immune reactions triggered by first-generation adenoviral 
vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther ;7:1455–1463. 
 
Hearing, P., Samulski, R.J., Wishart, W.L., And Shenk, T. (1987). 
Identification of a repeated sequence element required for efficient encapsidation 
of the adenovirus type 5 chromosome. J. Virol. 61, 2555–2558. 
 - 77 - 
Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, 
Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel 
DT.(2003) A canine conditionally replicating adenovirus for evaluating oncolytic 
virotherapy in a syngeneic animal model. Mol Ther ;7:163–173. 
 
Higginbotham, J.N., Seth, P., Blaese, R.M., Ramsey, W. J. (2002), The release 
of inflammatory cytokines from human peripheral blood mononuclear cells in 
vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther., 
2002. 13(1): 129-141. 
 
Hofmann C, Loser P, Cichon G, Arnold W, Both GW, Strauss M.(1999) 
Ovine adenovirus vectors overcome preexisting humoral immunity against human 
adenoviruses in vivo. J Virol ;73:6930–6936. 
 
Honda, T., Saitoh, H., Masuko, M., Katagiri-Abe, T.,Tominaga, K., Kozakai, 
I., Kobayashi, K., Kumanishi,T., Watanabe, Y.G., Odani, S., And Kuwano, 
R. (2000). The coxsackievirus–adenovirus receptor protein as a cell adhesion 
molecule in the developing mouse brain. Brain Res. Mol. Brain Res. 77,19–28. 
 
Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA.(1997) 
Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface 
of human epithelial and B lymphoblastoid cells. EMBO J;16:2294–2306. 
 
Ilan Y, Jona VK, Sengupta K, Davidson A, Horwitz MS, Roy-Chowdhury N, 
Roy-Chowdhury J. (1997) Transient immunosuppression with FK506 permits 
long-term expression of therapeutic genes introduced into the liver using 
recombinant adenoviruses in the rat. Hepatology ;26:949–956 
 
Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, 
Davidson A, Ott M, Horwitz MS, Chowdhury JR(1998) Oral tolerization to 
adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats 
with pre-existing immunity to adenoviruses. Hepatology27:1368–1376. 
 
Ilan, Y., Droguett, G., Chowdhury, N.R., Li, Y., Sengupta, K., Thummala, 
N.R., Davidson, A., Chowdhury, J.R., And Horwitz, M.S. (1997). Insertion of 
the adenoviral E3 region into a recombinant viral vector prevents antiviral 
humoral and cellular immune responses and permits long-term gene expression. 
Proc. Natl. Acad. Sci. U.S.A. 94, 2587–2592. 
 
Ito, H.O., So, T., Hirata, M., Koga, T., Ueda, T. and Imoto, T. (1998), 
Tolerogenic activity of polyethylene glycolconjugated lysozyme distinct from that 
of the native counterpart. Immunology,93(2): 200-207. 
 
Janeway CA, Travers P. (1997) The humoral immune response. In: Austin P, 
Lawrence E, Robertson M, editors. Immunobiology: the immune system in health 
and disease, vol. 8 (1–8). New York: Garland; 1997. p. 54. 
 
 - 78 - 
Javier, R., Raska, K., Jr., Macdonald, G.J., and Shenk, T. (1991). Human 
adenovirus type 9-induced rat mammary tumors. J. Virol. 65, 3192–3202. 
 
Jones, N., And Shenk, T. (1978). Isolation of deletion and substitution mutants 
of adenovirus type 5. Cell 13, 181–188. 
 
Jooss K, Turka LA, Wilson JM (1998) Blunting of immune responses to 
adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther ;5:309–
319. 
 
Jooss, K., and Chirmule, N.(2003) , Immunity to adenovirus and adeno-
associated viral vectors: implications for gene therapy. Gene Ther.10(11): 955-
963. 
 
Jooss, K., Ertl, H.C., and Wilson, J.M (1998)., Cytotoxic T-lymphocyte target 
proteins and their major histocompatibility complex class I restriction in response 
to adenovirus vectors delivered to mouse liver. J. Virol., 72(4): 2945-2954. 
 
Kafri T, Morgan D, Krahl T, et al (1998). Cellular immune response to 
adenoviral vector infected cells does not require de novo viral gene expression: 
implications for gene therapy. Proc Natl Acad Sci USA 1998;95:11377–82. 
 
Kaplan JM, Smith AE.(1997) Transient immunosuppression with 
deoxyspergualin improves longevity of transgene expression and ability to 
readminister adenoviral vector to the mouse lung. Hum Gene Ther;8:1095–1104 
 
Kelkar, S.A., Pfister, K.K., Crystal, R.G., and Leopold, P.L. (2004). 
Cytoplasmic dynein mediates adenovirus binding to microtubules. J. Virol. 78, 
10122–10132. 
 
Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L.(2001) Lifetime correction 
of genetic deficiency in mice with a single injection of helper-dependent 
adenoviral vector. Proc Natl Acad Sci USA;98:13282– 13287.  
 
Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT.(2001) 
Genetic targeting of an adenovirus vector via replacement of the fiber protein with 
the phage T4 fibritin. J Virol ;75:4176–4183. 
 
Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, 
Wadsworth S, O'Riordan C. (2003) Targeting adenoviral vectors using 
heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther ;8:99–107. 
 
Lang, S.E., And Hearing, P. (2003). The adenovirus E1A oncoprotein recruits 
the cellular TRRAP/GCN5 histone acetyltransferases complex. Oncogene 22, 
2836–2841. 
 
Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR (2003). 
Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol ;75:5405–5409. 
 - 79 - 
Li, E., Stupack, D., Bokoch, G. M. & Nemerow, G. R. (1998). Adenovirus 
endocytosis requires actin cytoskeleton reorganization mediated by Rho family 
GTPases. Journal of Virology 72, 8806±8812. 
 
Lieber, A., He, C.Y., Meuse, L., Schowalter, D., Kirillova, I., Winther, B. and 
Kay, M.A.(1997) , The role of Kupffer cell activation and viral gene expression 
in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol., 
71(11): 8798-8807. 
 
 
Linsley PS, Brady W, Grosmaire L, et al.(1991) Binding of the B cell activation 
antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA 
accumulation. J Exp Med;173:721 30. 
 
Lomotan EA, Brown KA, Speaker TJ, Offita PA.(1997) Aqueous-based 
microcapsules are detected primarily in gut-associated dendritic cells after oral 
inoculation of mice. Vaccine;15:1959–1962. 
 
Lozier, J.N., Csako, G., Mondoro, T.H., Krizek, D.M., Metzger, M.E., 
Costello, R., Vostal, J.G., Rick, M.E., Donahue, R.E., Morgan, R.A.(2002), 
Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene 
Ther.,13(1): 113-124. 
 
Lozier, J.N., Metzger, M.E., Donahue, R.E., and Morgan, R.A., (1999) 
Adenovirus-mediated expression of human coagulation factor IX in the rhesus 
macaque is associated with dose-limiting toxicity. Blood,  94(12): 3968-3975. 
 
Mangel, W.F., Baniecki, M.L., And Mcgrath, W.J. (2003). Specific 
interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid 
viral peptide, and the cellular protein actin. Cell. Mol. Life Sci. 60, 2347–2355 
 
 Maraskovsky E, Chen WF, Shortman K. (1989) IL-2 and IFN-gamma are two 
necessary lymphokines in the development of cytolytic T cells. J 
Immunol;143:1210–4. 
 
Matthews, D. A. & Russell, W. C. (1995). Adenovirus protein±protein 
interactions : molecular parameters governing the binding of protein VI to hexon 
and the activation of the adenovirus 23K protease. Journal of General Virology 
76, 1959±1969. 
 
Maul, G.G. (1998). Nuclear domain 10, the site of DNA virus transcription and 
replication. Bioessays 20, 660–667. 
 
Meier, O., Boucke, K., Hammer, S.V., Keller, S., Stidwill, R.P., Hemmi, S., 
and Greber, U.F. (2002). Adenovirus triggers macropinocytosis and endosomal 
leakage together with its clathrin-mediated uptake. J. Cell Biol. 158, 1119–1131 
 
 
 - 80 - 
Mette, S. A., Pilewski, J., Buck, C. A. & Albelda, S. M. (1993). Distribution of 
integrin cell adhesion receptors on normal bronchial epithelial cells and lung 
cancer cells in vitro and in vivo. American Journal of Research in Respiratory 
Cell and Molecular Biology 8, 562±572. 
 
Mingozzi F, Liu YL, Dobrzynski E, et al.(2003) Induction of immune tolerance 
to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 
;111:1347–56. 
 
Mitani K, Wakamiya M, Hasty P, Graham FL, Bradley A, Caskey CT.(1995) 
Gene targeting in mouse embryonic stem cells with an adenoviral vector. Somat 
Cell Mol Genet ;21:221–231. 
 
Mittal SK, Aggarwal N, Sailaja G, van Olphen A, HogenEsch H, North A, 
Hays J, Moffatt S.(2000) Immunization with DNA, adenovirus or both in 
biodegradable alginate microspheres: effect of route of inoculation on immune 
response. Vaccine ;19:253–263. 
 
Moffatt S, Hays J, HogenEsch H, Mittal SK.(2000) Circumvention of vector-
specific neutralizing antibody response by alternating use of human and non-
human adenoviruses: implications in gene therapy. Virology ;272:159–167. 
 
Molinier-Frenkel V, Prevost-Blondel A, Hong SS, Lengagne R, Boudaly S, 
Magnusson MK, Boulanger P, Guillet JG.(2003) The maturation of murine 
dendritic cells induced by human adenovirus is mediated by the fiber knob 
domain. J Biol Chem;278:37175–37182. 
 
Morral N, O’Neal W, Zhou H, Langston C, Beaudet A.(1997) Immune 
responses to reporter proteins and high viral dose limit duration of expression with 
adenoviral vectors: comparison of E2a wild-type and E2a deleted vectors. Hum 
Gene Ther;8:1275–86. 
 
Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, 
Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek 
S, Carey KD, Beaudet AL.(1999)  Administration of helperdependent adenoviral 
vectors and sequential delivery of different vector serotype for long-term 
liverdirected gene transfer in baboons. Proc Natl Acad Sci USA ;96:12816–
12821. 
 
Morral, N., O'Neal, W.K., Rice, K., Leland, M.M., Piedra, P.A., Aguilar-
Cordova, E., Carey, K.D., Beaudet, A.L. and Langston, C., (2002) Lethal 
toxicity, severe endothelial injury, and a threshold effect with high doses of an 
adenoviral vector in baboons. Hum. Gene Ther.,13(1): 143-154. 
 
 
 
 
 - 81 - 
Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks 
RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT. (1998) An adenoviral 
vector deleted for all viral coding sequences results in enhanced safety and 
extended expression of a leptin transgene. Proc Natl Acad Sci USA;95:7866–
7871. 
 
Muruve, D.A., Barnes, M. J., Stillman, I. E., and Libermann, T. A., (1999) 
Adenoviral gene therapy leads to rapid induction of multiple chemokines and 
acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther., 10: 965-976. 
Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt 
DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A,  
 
Mansfield KG, Havenga MJ, Barouch DH.(2005) Immunogenicity of 
recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice 
and rhesus monkeys. J Virol;79:14161–14168. 
 
Nunes, F.A., Furth, E.E., Wilson, J.M., Raper, S.E., (1999) Gene transfer into 
the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: 
safety of readministration. Hum. Gene Ther., 10(15): 2515-2526. 
 
O'Riordan, C., (2002) The Humoral Immune Response, In Adenoviral Vectors 
for Gene Therapy, Curiel, D. and Douglas, J., Eds, Academic Press: San Diego. p. 
375-407. 
 
Ostapchuk P, Hearing P. (2001) Pseudopackaging of adenovirus type 5 genomes 
into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J 
Virol;75:45–51. 
 
Palmer, D., and Ng, P. (2003). Improved system for helper-dependent adenoviral 
vector production. Mol. Ther. 8, 846–852. 
 
Parks R, Chen L, Anton M, Sankar U, Rudnicki M, Graham F (1996). A new 
helper-dependent adenovirus vector system: removal of helper virus by Cre-
mediated excision of the viral packaging signal. Proc Natl Acad Sci 
USA;93:13565–13570. 
 
Parks R, Evelegh C, Graham F(1999). Use of helper-dependent adenoviral 
vectors of alternative serotypes permits repeat vector administration. Gene Ther 
;6:1565–1573. 
 
Pastore, L., Belalcazar, L.M., Oka, K., Cela, R., Lee, B., Chan, L., and 
Beaudet, A.L. (2004). Helper-dependent adenoviral vector-mediated long-term 
expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient 
mice. Gene 327, 153–160. 
 
 
 
 - 82 - 
Pastore, L., Morral, N., Zhou, H., Garcia, R., Parks, R.J., Kochanek, S., 
Graham, F.L., Lee, B., Beaudet, A.L.,(1999) Use of a liver-specific promoter 
reduces immune response to the transgene in adenoviral vectors. Hum. Gene 
Ther.,10(11): 1773-1781. 
 
Paul WE, Seder RA. (1994) Lymphocyte responses and cytokines. Cell ;76:241–
51. 
 
Perez, D., And White, E. (2000). TNF-α signals apoptosis through a bid-
dependent conformational change in Bax that is inhibited by E1B 19K. Mol. Cell 
6, 53–63. 
 
Pilder, S., Moore, M., Logan, J., and Shenk, T. (1986). The adenovirus E1B-
55K transforming polypeptide modulates transport or cytoplasmic stabilization of 
viral and host cell mRNAs. Mol. Cell. Biol. 6, 470–476. 
 
Quimby, F.W.,(1999)  The Mouse, In The Clinical Chemistry of Laboratory 
Animals, W.F. Loeb, and Quimby, F. W., Editor. Taylor and Francis: 
Philadelphia. p. 3-33. 
 
Raper SE, Yudkoff M, Chirmule N, et al. (2002) A pilot study of in vivo liver-
directed gene transfer with an adenoviral vector in partial ornithine 
transcarbamylase deficiency. Hum Gene Ther ;13:163– 75. 
 
Raper, S.E., Chirmule, N., Lee, F. S.,Wivel, N. A., Bagg, A., Gao, G. P., 
Wilson, J. M., and Batshaw, M. L. (2003) , Fatal systemic inflammatory 
response syndrome in a ornithine transcarbamylase deficient patient following 
adenoviral gene transfer. Mol. Genet. Metab., 80(1-2): 148-158. 
 
Raper, S.E., Yudkoff, M., Chirmule, N., Gao, G.P., Nunes, F., Haskal, Z.J., 
Furth, E.E., Propert, K.J., Robinson, M.B., Magosin, S., Simoes, H., 
Speicher, L., Hughes, J., Tazelaar, J., Wivel, N.A., Wilson, J.M., and 
Batshaw, M.L.(2002), A pilot study of in vivo liver-directed gene transfer with 
an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene 
Ther.,13(1): 163-175. 
 
Rauma, T., Tuukkanen, J., Bergelson, J. M., Denning, G. & Hautala, T. 
(1999). rab5 GTPase regulates adenovirus endocytosis. Journal of Virology 73, 
9664±9668. 
 
Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA, Kiertscher 
SM.(2002) Helper-dependent adenoviral vectors efficiently express transgenes in 
human dendritic cells but still stimulate antiviral immune responses. J 
Immunol;169:4651–4656. 
 
 
 - 83 - 
Routes, J.M., Ryan, S., Clase, A., Miura, T., Kuhl, A., Potter, T.A., and Cook, 
J.L. (2000). Adenovirus E1A oncogene expression in tumor cells enhances killing 
by TNF-related apoptosisinducing ligand (TRAIL). J. Immunol. 165, 4522–4527. 
 
Rowe, W. P., Huebner, R. J., Gilmore, L. K., Parrot, R. H. & Ward, T. 
G.(1953). Isolation of a cytopathic agent from human adenoids undergoing 
spontaneous degradation in tissue culture. Proceedings of the Society for 
Experimental Biology and Medicine 84, 570±573. 
 
Sailaja G, HogenEsch H, North A, Hays J, Mittal SK.(2002) Encapsulation of 
recombinant adenovirus into alginate microspheres circumvents vector-specific 
immune response. Gene Ther;9:1722–1729. 
 
Sakhuja, K., et al. (2003). Optimization of the generation and propagation of 
gutless adenoviral vectors. Hum. Gene Ther. 14: 243–254. 
 
Sandig, V., Youil, R., Bett, A.J., Franlin, L.L., Oshima, M., Maione, D., 
Wang, F., Metzker, M.L., Savino, R., Andcaskey, C.T. (2000). Optimization of 
the helper-dependent adenovirussystem for production and potency in vivo. Proc. 
Natl. Acad.Sci. U.S.A. 97, 1002–1007. 
 
Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S 
(2003b). Selective depletion or blockade of Kupffer cells leads to enhanced and 
prolonged hepatic transgene expression using high-capacity adenoviral vectors. 
Mol Ther;7:35–43. 
 
Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, 
Graham FL, Beaudet AL, Kochanek S (1998). Genomic DNA transfer with a 
high-capacity adenovirus vector results in improved in vivo gene expression and 
decreased toxicity. Nat Genet ;18:180–183. 
 
Schnell, M.A., Zhang, Y., Tazelaar, J., Gao, G.-P., Yu, Q., Chen, S.-J., 
Varnavski, A. N., LeClair, S., Raper, S. E. and Wilson J. M.,(2001) Activation 
of Innate Immunity in Nonhuman Primates Following Intraportal Administration 
of Adenoviral Vectors. Molec. Ther., 3(5): 708-722. 
 
Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E.(2005) Influence of 
fiber detargeting on adenovirusmediated innate and adaptive immune activation. J 
Virol ;79:11627–11637. 
 
Schowalter, D.B., Himeda, C.L., Winther, B.L., Wilson, C.B., and Kay, M.A., 
(1999) Implication of interfering antibody formation and apoptosis as two 
different mechanisms leading to variable duration of adenovirusmediated 
transgene expression in immune-competent mice. J. Virol., 1999. 73(6): 4755-
4766. 
 
 
 - 84 - 
Schowalter, D.B., Tubb, J.C., Liu, M., Wilson, C.B., and Kay, M.A. (1997). 
Heterologous expression of adenovirus E3- gp19K in an E1a-deleted adenovirus 
vector inhibits MHC I expression in vitro, but does not prolong transgene 
expression in vivo. Gene Ther. 4, 351–360. 
 
Scott, M.D., Murad, K.L.,(1998) Cellular camouflage: fooling the immune 
system with polymers. Curr. Pharm. Des. 4(6): 423-438. 
 
Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. 
(2003)  Adenovirus type 11 uses CD46 as a cellular receptor. J Virol;77:9183–
9191. 
 
Sehon, A.H., Carl Prausnitz (1991) Suppression of antibody responses by 
chemically modified antigens. Int Arch Allergy Appl Immunol, 94(1-4): 11-20. 
 
Shenk, T. (1996). Adenoviridae: The viruses and their replication. In Virology. 
B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, New York) 
pp. 2111–2148. 
 
Shiver JW, Emini EA.(2004) Recent advances in the development of HIV-1 
vaccines using replicationincompetent adenovirus vectors. Annu Rev Med 
;55:355–372. 
 
Shtrichman, R., Sharf, R., Barr, H., Dobner, T., and Kleinberger, T. (1999). 
Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed 
cells and requires an interaction with protein phosphatase 2A. Proc. Natl. Acad. 
Sci. U.S.A. 96, 10080–10085. 
 
Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, Vogt L, 
Ruedl C, Bachmann MF, Greber UF, Hemmi S.(2004) The human membrane 
cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 
;78:4454–4462. 
 
Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, 
Nemerow GR, Kaleko M, Stevenson SC.(2003) Adenovirus serotype 5 fiber 
shaft influences in vivo gene transfer in mice. Hum Gene Ther ;14:777–787. 
 
Smith TA, White BD, Gardner JM, Kaleko M, McClelland A.(1996) Transient 
immunosuppression permitssuccessful repetitive intravenous administration of an 
adenovirus vector. Gene Ther 13:496–502. 
 
So, T., Ito, H.-O., Hirata, M., Ueda, T. and Imoto, T.(1999), Extended blood 
half-life of monomethoxypolyethylene glycol-conjugated hen lysozyme is a key 
parameter controlling immunological tolerogenicity. Cell. Mol. Life Sci.,55: 
1187-1194 
 
 - 85 - 
Steel JC, Cavanagh HM, Burton MA, Kalle WH.(2004) Microsphere-liposome 
complexes protect adenoviral vectors from neutralising antibody without losses in 
transfection efficiency, in-vitro. J Pharm Pharmacol;56:1371–1378. 
 
Stewart, P. L., Fuller, S. D. & Burnett, R. M. (1993). Difference imaging of 
adenovirus : bridging the resolution gap between X-ray crystallography and 
electron microscopy. EMBO Journal 12, 2589±2599 
 
Stewart, P.L., Chiu, C.Y., Huang, S., Muir, T., Zhao, Y., Chait, B., Mathias, 
P., and Nemerow, G.R. (1997). Cryo-EM visualization of an exposed RGD 
epitope on adenovirus that escapes antibody neutralization. EMBO J. 16, 1189–
1198 
 
Stracker, T.H., Carson, C.T., and Weitzman, M.D. (2002). Adenovirus 
oncoproteins inactivate the Mre11–Rad50–NBS1 DNA repair complex. Nature 
418, 348–352. 
 
Sundararajan, R., Cuconati, A., Nelson, D., And White, E. (2001). Tumor 
necrosis factor-_ induces Bax–Bak interaction and apoptosis, which is inhibited 
by adenovirus E1B 19K. J. Biol. Chem. 276, 45120–45127 
 
Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W., And Wold, W.S. 
(1996a). The E3-11.6-kDa adenovirus death protein (ADP) is required for 
efficient cell death: Characterization of cells infected with adp mutants. Virology 
220, 152–162. 
 
Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J., And 
Wold, W.S. (1996b). The adenovirus death protein (E3-11.6K) is required at very 
late stages of infection for efficient cell lysis and release of adenovirus from 
infected cells. J. Virol. 70, 2296–2306. 
 
Tomko RP, Xu R, Philipson L. (1997) HCAR and MCAR: the human and 
mouse cellular receptors for subgroup C adenoviruses and group B 
coxsackieviruses. Proc Natl Acad Sci USA;94:3352–3356. 
 
Trapnell, B.C., Shanley, T. P. (2002) Innate Immune Response to In Vivo 
Adenovirus Infection, In Adenoviral Vectors for Gene Therapy, Curiel, D. and 
Douglas, J. T., Eds.Academic Press: San Diego. p. 349-373. 
 
Tripathy, S.K., Goldwasser, B. H., and Leiden, J. M., (1996) Immune 
Responses to Transgene-Encoded Proteins Limit the Stability of Gene Expression 
after Injection of Replication-Defective Adenovirus Vectors. Nature Med.,22: 
545-550. 
 
Trotman, L.C., Mosberger, N., Fornerod, M., Stidwill, R.P., and Greber, U.F. 
(2001). Import of adenovirus DNA involves the nuclear pore complex receptor 
CAN/Nup214 and histone H1 
 - 86 - 
Umana, P., Gerdes, C.A., Stone, D., Davis, J.R., Ward, D.,Castro, M.G., and 
Lowenstein, P.R. (2001). Efficient FLPerecombinase enables scalable production 
of helper-dependent adenoviralvectors with negligible helper-virus contamination. 
Nat. Biotechnol. 19, 582–585. 
 
van Olphen AL, Tikoo SK, Mittal SK (2002). Characterization of bovine 
adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 
295:108–118. 
 
Varnavski AN, Zhang Y, Schnell M, et al.(2002) Preexisting immunity to 
adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol. 
76:5711–9. 
 
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR.(1993) Integrins alpha v 
beta 3 and alpha v beta 5 promote adenovirus internalization but not virus 
attachment. Cell. 73:309–319. 
 
Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG (1997). 
Role of alveolar macrophages in rapid elimination of adenovirus vectors 
administered to the epithelial surface of the respiratory tract. Hum Gene Ther. 
8:1675–1684. 
 
Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G., (1997) Innate 
immune mechanisms dominate elimination of adenoviral vectors following in 
vivo administration. Hum. Gene Ther. 1997. 8(1): 37-44. 
 
Working, P.K., Newman, M. S., Johnson, J. and Cornacoff, J. B.(1997), 
Safety of Poly(ethylene glycol) and Poly(ethylene glycol) derivatives, In 
Poly(ethylene glycol) Chemistry and Biological Applications, J.M. Harris, and 
Zalipsky, S., Eds., American Chemical Society: Washington. D.C. p. 45-57. 
 
Yang Y, Wilson JM. (1995) Clearance of adenovirus-infected hepatocytes by 
MHC class I-restricted CD4+ CTLs in vivo. J Immunol.155:2564–70. 
 
Yang Y, Xiang Z, Ertl HC, Wilson JM. (1995) Upregulation of class I major 
histocompatibility complex antigens by interferon gamma is necessary for T-cell-
mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. 
Proc Natl Acad Sci USA. 92:7257–61. 
 
Yang, Y., Ertl, H. C. J., and Wilson, J. M. (1994), MHC Class I-Restricted 
Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice 
Infected with E1-Deleted Recombinant Adenoviruses. Immunity. 1: 433-442. 
 
Yang, Y., Jooss, K., Su, Q., Ertl, H.C., and Wilson J. M.(1996) , Immune 
Responses to Viral Antigens Versus Transgene Product in the Elimination of 
Recombinant Adenovirus-Infected Adenovirus Hepatocytes in vivo. Gene Ther. 3: 
137-144. 
 - 87 - 
Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gönczöl, E., and Wilson, 
J.M. (1994a). Cellular immunity to viral antigens E1-deleted adenoviruses for 
gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407–4411. 
 
Yang, Y., Nunes, F.A., Berencsi, K., Gonczol, E., Engelhardt, J.F., and 
Wilson, J.M. (1994b). Inactivation of E2a in recombinant adenoviruses improves 
the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7, 362–369. 
 
Ye X, Robinson MB, Pabin C, Batshaw ML, Wilson JM (2000) Transient 
depletion of CD4 lymphocyte improves efficacy of repeated administration of 
recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur 
mouse. Gene Ther.7:1761–1767. 
 
Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner 
MK.(2002) Bilamellar cationic liposomes protect adenovectors from preexisting 
humoral immune responses. Mol Ther;5:233–241.  
 
Zakhartchouk A, Connors W, van Kessel A, Tikoo SK.(2004) Bovine 
adenovirus type 3 containing heterologous protein in the C-terminus of minor 
capsid protein IX. Virology 320:291–300. 
 
Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J, 
Wilson JM(2001) Acute cytokine response to systemic adenoviral vectors in mice 
is mediated by dendritic cells and macrophages. Mol Ther 3:697–707. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 88 - 
INDEX 
 
CHAPTER I ........................................................................................................- 1 - 
INTRODUCTION ..............................................................................................- 1 - 
1. GENE THERAPY...........................................................................................- 1 - 
2. BIOLOGY AND VIRAL LIFE CYCLE OF ADENOVIRUS .......................- 3 - 
2.1 DESCRIPTION AND GENERAL PROPERTIES OF ADENOVIRUSES ..................... - 3 - 
2.2 THE VIRAL LIFE CYCLE ............................................................................... - 6 - 
2.2.1 Binding and entry ........................................................................... - 6 - 
2.2.2 Early genes and DNA replication ..................................................- 10 - 
2.2.3 Late gene expression and viral assembly .......................................- 13 - 
3. ADENOVIRUSES AS VECTORS...............................................................- 15 - 
3.1 FIRST-GENERATION VECTORS ................................................................... - 15 - 
3.2 SECOND-GENERATION VECTORS ............................................................... - 17 - 
3.3 HELPER-DEPENDENT VECTORS ................................................................. - 18 - 
3.4 INDUCTION OF INNATE IMMUNE RESPONSE AND TOXICITY BY ADENOVIRAL 
VECTORS ........................................................................................................ - 20 - 
4. STRATEGIES FOR CIRCUMVENTION OF VECTOR IMMUNITY ......- 27 - 
4.1 IMMUNOSUPRESSION OR IMMUNOMODULATION ....................................... - 27 - 
4.2 ALTERING NATIVE AD VECTOR AND CELL SURFACE RECEPTOR INTERACTIONS - 
28 - 
4.3 VECTOR MICROENCAPSULATION .............................................................. - 31 - 
4.4 USE OF ALTERNATE HAD SEROTYPES (SEROTYPE SWITCHING).................. - 32 - 
4.5 USE OF HELPER-DEPENDENT AD (HD-AD) VECTORS .............................. - 32 - 
4.6 USE OF NONHUMAN AD VECTORS ........................................................... - 33 - 
5. PEGYLATION OF ADENOVIRAL VECTORS.........................................- 34 - 
5.1 PRELIMINARY STUDIES ............................................................................. - 35 - 
CHAPTER II.....................................................................................................- 41 - 
MATERIALS AND METHODS......................................................................- 41 - 
1. HD∆28E4LACZ PRODUCTION.................................................................- 41 - 
1.1 HELPER VIRUS .......................................................................................... - 41 - 
1.2 PRODUCER CELL LINE 116 ........................................................................ - 41 - 
1.3.................................................................................................................. - 42 - 
1.4 HD∆28E4LACZ PURIFICATION ................................................................ - 44 - 
1.5 SOUTHERN ANALYSIS FOR HELPER VIRUS CONTAMINATION OF 
HD∆28E4LACZ............................................................................................. - 44 - 
1.6 HD∆28E4LACZ PEGYLATION ................................................................ - 45 - 
1.7 CHARACTERIZATION OF PEGYLATED HD-AD VECTORS: CAPILLARY ZONE 
ELECTROPHORESIS.......................................................................................... - 45 - 
2. ANIMAL STUDIES .....................................................................................- 46 - 
 - 89 - 
2.1 BIOCHEMICAL ANALYSIS .......................................................................... - 46 - 
2.2 NEUTRALIZATION ASSAY.......................................................................... - 47 - 
2.3 X-GAL HISTOCHEMISTRY.................................................................... - 47 - 
3. REAL- TIME PCR........................................................................................- 48 - 
CHAPTER III ...................................................................................................- 49 - 
RESULTS .........................................................................................................- 49 - 
1.  HD∆28E4LACZ PRODUCTION IN 116 CELL LINE ....................................... - 49 - 
1.1HD∆28E4LACZ PEGYLATION ................................................................. - 54 - 
2. TOXICITY PROFILES OF PEGYLATED HD-AD....................................- 56 - 
2.1 TISSUE DAMAGE ....................................................................................... - 56 - 
2.2 COAGULOPATHY ...................................................................................... - 56 - 
2.3 ACUTE INFLAMMATION ............................................................................ - 57 - 
2.4 IN VIVO PERFORMANCE OF PEGYLATED HD-AD ..................................... - 58 - 
3.  BIODISTRIBUTION OF PEGYLATED VECTORS IN VIVO ................................ - 66 - 
CHAPTER IV ...................................................................................................- 69 - 
DISCUSSION ...................................................................................................- 69 - 
BIBLIOGRAPHY.............................................................................................- 72 - 
INDEX………………………………………………………………………...- 88 - 
 
